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Abstract 
 
Objectives 
 
1. To survey the current practice of image-guided radiotherapy 
(IGRT) for prostate cancer in the United Kingdom. 
2. To validate a practical dose calculation strategy on cone-beam 
computed tomography (CBCT) 
3. To assess the effect of CBCT verification imaging frequency on 
actual dose delivered to target volume and organs at risk during 
a course of image-guided radiotherapy for prostate cancer. 
4. To compare the dosimetric effects of reduction of CTV-PTV 
margin with daily imaging. 
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Material and Methods 
 
59 radiotherapy centres in the United Kingdom were included in an online 
survey of IGRT practice. The survey covered details of verification strategy 
during prostate radiotherapy, with specific questions on imaging 
frequency. 
 
A validation study of the CBCT dose calculation strategy was evaluated on 
37 fractions using Bland-Altman plots. The study technique was compared 
to the density-override technique. A pilot comparison of CTV coverage 
with bone matching to soft tissue matching was performed. 
 
For the principal dosimetric analysis, 844 cone-beam CT (CBCT) images 
from 20 patients undergoing radical prostate radiotherapy were included. 
Patients received a dose of 74 Gy in 37 fractions using 7-field intensity-
modulated radiotherapy. Target volume and organs at risk were contoured 
manually on each CBCT image.   
 
A daily online CBCT verification schedule was compared with a protocol of 
day 1-3 followed by weekly imaging. 3 mm, 5 mm, and 7 mm CTV-PTV 
margins were compared for daily imaging. 
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Results 
 
CBCT is the principal verification imaging modality in the UK for prostate 
cancer, used by 66% of centres. There is no consensus on optimal 
imaging schedule, with 2 main strategies used. These are the daily online 
schedule and the day 1-3 followed by weekly schedule. 
 
Use of CBCT contours on planning CT showed good agreement with the 
density-override technique, provided multifield IMRT was used. There 
were clear drops in target coverage if a bone match strategy was used in 
comparison to soft tissue matching. 
 
90% of patients had improved target coverage with daily online in 
comparison to weekly online soft tissue match. A median of 37 fractions 
achieved CTV coverage with daily imaging compared with 34 fractions 
with a weekly online protocol. 80% of patients had a reduction in rectal 
dose with the daily protocol. Margin reduction to 5 mm with adequate 
target coverage was feasible with daily imaging. 
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Conclusions 
 
Daily online CBCT verification improves CTV coverage and reduces rectal 
dose during IGRT for prostate cancer. Daily CBCT imaging allows 
reduction of CTV-PTV margin for radiotherapy.  
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Chapter 1. Introduction 
 
Image Guided Radiotherapy (IGRT) is the use of imaging in the treatment 
room either immediately before or during treatment to evaluate and correct 
setup errors (Royal College of Radiologists et al., 2008). 
 
1.1 History of IGRT technology 
 
Strategies to improve radiotherapy accuracy during the early years of 
radiotherapy focussed on patient immobilization, with large margins to 
allow for error. A few institutions introduced imaging devices in the late 
20th century. Holloway reported the use of a x-ray camera mounted on the 
gantry of a cobalt machine in 1958 (Holloway, 1958). A similar device for 
cobalt-60 radiotherapy was also reported in 1959 (Johns and 
Cunningham, 1959). However, the use of these imaging devices was 
limited to a few research-oriented institutions.  
 
When linear accelerators were introduced in the 1950s, first at the 
Hammersmith Hospital in London (Miller, 1954), and subsequently in 
Stanford University, image-guidance was not available on the treatment 
machine. It was only after 1985 that x-ray imaging devices were 
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incorporated into linear accelerators (Biggs et al., 1985), but even this was 
not adopted immediately due to restriction of collimator by the device. 
Electronic portal imaging technology for 2-D planar imaging was 
developed in Harvard (Leong, 1986) and reported in the Netherlands in 
1985 (van Herk and Meertens).  
 
3-D imaging using cone beam CT was subsequently developed. The 
algorithms for cone beam CT reconstruction after arc acquisition were 
developed in the late 1990s (Wang and Ning, 1999). Flat panel detectors 
were then optimized for radiotherapy use (Jaffray and Siewerdsen, 2000). 
The first implementation of cone beam CT using a kilovoltage (kV) source 
and flat-panel detectors in a medical linear accelerator was described in 
2002 (Jaffray et al., 2002). The technology will be discussed in detail 
further in this manuscript. 
 
There is continuing progress in image-guided radiotherapy, with the 
development of prototype hybrid MRI-linear accelerators (Lagendijk et al., 
2008, Keall et al., 2014, Stanescu et al., 2013). 
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1.2 External beam radiotherapy for prostate cancer 
 
Radical external beam radiotherapy is a very effective treatment modality 
for localized prostate cancer, with outcomes at least as good as prostate 
surgery (D'Amico et al., 1998). Brachytherapy using direct radiotherapy 
sources for localized prostate cancer is another effective treatment 
modality which is outside the scope of this work. The curative efficacy of 
radiation treatment should be balanced against toxicity to surrounding 
organs. These organs at risk include the bladder and rectum, and potential 
side effects may have long-term consequences on quality of life.  
 
Dose escalation has been attempted to improve cure rates further. 
Attempts at escalation of dose using older conformal radiotherapy led to 
improved progression-free survival, but higher rates of toxicity (Dearnaley 
et al., 2007, Zelefsky et al., 1998). The use of intensity-modulated 
radiotherapy (IMRT) has led to reduced toxicity (Zelefsky et al., 2002), due 
to improved dosimetric characteristics (Vanasek et al., 2013). However, 
further improvement of outcomes in prostate radiotherapy requires 
intensive management of sources of error during treatment. This is the 
basis for the use of advanced image guidance in image-guided 
radiotherapy (IGRT). 
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1.3 Sources of error in prostate radiotherapy 
 
The causes of local failure of prostate radiotherapy could be classified in 
several ways. It may be classified as treatment-related factors or tumour-
related factors. Tumour factors such as intrinsic radio-resistance are 
outside the scope of this work. Treatment factors include the multiple 
sources of error during radiotherapy, which occur throughout the process 
of treatment (Fig. 1).  
 
 
Fig. 1. Sources of error during radiotherapy 
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In the case of prostate radiotherapy, a key source of error is geometric 
uncertainty due to pelvic organ movement. In particular, rectal and bladder 
changes lead to prostate target movement and could lead to ‘geographic 
miss’. Rectal movement assessed using cine MRI has been shown to be 
associated with prostate movement, particularly if the rectum is distended 
(Padhani et al., 1999, Ghilezan et al., 2005). Highly conformal modern 
intensity-modulated radiotherapy utilizes steep dose gradients, and the 
effect of organ movement can lead to even greater errors. 
 
Discrepancies between intended and actual treatment positions during 
radiotherapy are referred to as setup errors. They have a systematic 
component and random component. A systematic error is a deviation that 
occurs in the same direction and is of similar magnitude throughout the 
course of radiotherapy (Royal College of Radiologists et al., 2008). It can 
occur due to errors in treatment preparation for example, organ motion 
between the planning scan and start of treatment. A random error is an 
error that can vary in deviation and magnitude during each fraction. For 
example, organ motion in between treatment fractions during treatment. 
  
Imaging prior to treatment has the potential to correct for inter-fraction 
variation due to organ motion. However, there can be other sources of 
residual errors such as rotational errors (Graf et al., 2012, Shang et al., 
2013), intrafraction motion (Kron et al., 2010, Thomas et al., 2013) and 
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registration errors (Morrow et al., 2012). Image guidance should therefore 
be used in conjunction with appropriate immobilization of the patient and 
with suitable margins to account for residual errors.  
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1.4 Clinical benefits of image-guided radiotherapy for 
prostate cancer 
 
Image-guided radiotherapy (IGRT) is becoming the standard of care for 
delivery of external beam radiation treatment for prostate cancer. The 
benefits of image-guided radiotherapy have been shown in retrospective 
patient series of fiducial-based IGRT. There have not been any 
randomized controlled trials directly comparing IGRT and non-IGRT 
approaches, due to ethical considerations. 
 
 A reduction in urinary toxicity has been clearly demonstrated in several 
studies (Zelefsky et al., 2012, Gill et al., 2011). In the Gill series, acute 
toxicity measured as urinary frequency more than grade 2 was 7% in the 
IGRT group compared with 23% in the non-IGRT group. Late urinary 
toxicity rates were 10.4% in the IGRT group in comparison to 20.0% in the 
non-IGRT group in the Zelefsky series.  
 
Other retrospective studies have shown reductions GI toxicity. Acute GI 
toxicity is lower, with one study showing a rate of 3% for GI toxicity (CTC 
grade 2 and higher) in the IGRT group in comparison with 15% in the non-
IGRT group (Gill et al., 2011). Late GI toxicity showed an even more 
prominent difference in another series. There was a rate of 6% GI toxicity 
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(greater than CTC grade 2) at 2 years in the IGRT group compared with 
57% in the non-IGRT group (Sveistrup et al., 2014).  
 
Zelefsky et al. also demonstrated improvements in biochemical control at 
three years for high-risk patients (Zelefsky et al., 2012). The prostate 
specific antigen (PSA) relapse-free survival rate was 97% in the IGRT 
group in comparison to 78% in the non-IGRT group. Cox regression 
analysis in the study confirmed IGRT as a positive predictive factor for 
biochemical control after radiotherapy for prostate cancer. 
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1.5 Strategies for image-guidance in prostate radiotherapy 
 
There are different strategies of image-guided radiotherapy and 
verification used in prostate treatment centres around the world. Imaging 
modalities for on-treatment verification have evolved from planar or 2-D 
imaging (such as MV portal imaging) to 3-D imaging (e.g. cone beam CT).  
4-D imaging where the tumour is imaged during the additional dimension 
of time has been less widely adapted in prostate cancer, although its use 
is common in lung cancer. Volumetric or 3-D imaging has emerged as the 
main verification modality in the US (Simpson et al., 2010), but there is no 
published survey data on prostate IGRT techniques used in the UK. 
 
A fiducial-based approach relies on matching implanted markers in the 
prostate to imaging obtained at treatment planning. The most commonly 
technique is the use of three small gold seeds implanted with the aid of a 
transrectal ultrasound probe. The fiducial markers are used as a proxy for 
the position of the prostate. However, in-migration can occur at a rate of 
approximately 0.05 mm per fraction (Nichol et al., 2007, Shirato et al., 
2003). Also, prostate deformation can be significant in some patients, 
particularly those who have previously had a transurethral resection of the 
prostate (TURP) (Nichol et al., 2007).   
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Another disadvantage of all fiducial-based systems is that an invasive 
procedure is required to implant markers prior to treatment. Serious 
complications such as sepsis are uncommon, but self-limiting low-grade 
side-effects are common. In the most cited series from the United 
Kingdom, 32% of patients developed at least one new symptom after the 
procedure (Gill et al., 2012). In another series from Australia, the rate of 
symptomatic infection was 7.7% with a third of those patients requiring 
hospital admission (Loh et al., 2015). 
 
Ultrasound-based pre-treatment and intra-treatment monitoring has been 
evaluated by some centres with promising results (Fargier-Voiron et al., 
2015). The use of magnetic electro-transponders such as the Calypso® 
system allows to real-time tracking of the fiducial markers during treatment 
(Willoughby et al., 2006, Kupelian et al., 2007). The Calypso® system has 
been found to be superior to standard transabdominal ultrasound 
verification (Foster et al., 2010). In the United Kingdom, use of 
transperineal ultrasound using the Elekta Clarity® system has been 
reported by one centre (Hilman et al.). Although good agreement has been 
obtained by the use of transperineal ultrasound, they have reported that 
radiographer training for optimal imaging has been challenging. 
 
Stereotactic radiotherapy using the Cyberknife® (Accuray Technologies) 
system uses repeated stereoscopic x-ray monitoring of fiducial markers 
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during hypofractionated prostate radiotherapy. Although the precision of 
the system is very good, an adequate sampling rate of at least an x-ray 
every 40 seconds is required to ensure submillimetre tracking (Xie et al., 
2008).  
 
There is continuing progress in image-guided radiotherapy, with the 
development of prototype hybrid MRI-linear accelerators (Lagendijk et al., 
2008, Keall et al., 2014, Stanescu et al., 2013). These could provide much 
better soft-tissue contrast, overcoming the image quality drawbacks with 
cone beam CT. There are also no concomitant radiation dose issues, and 
there is greater scope for real-time adaptive radiotherapy. 
 
The challenges of MRI integration are due to two factors. The first is the 
radio-frequency (RF) signal used in the MRI system interfering with the RF 
pulses used to accelerate electrons in the linear accelerator. The other is 
the strong magnetic field of the MRI potentially affecting secondary 
electron distribution in the patient during treatment. These challenges are 
being circumvented and working prototypes have been developed.   
 
However, MRI linear accelerators are still a research technology limited to 
a few centres in the UK. In view of the costs involved, it is likely to be 
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many years before MRI-integrated linear accelerators come into 
widespread use in the UK National Health Service.  
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1.6 Comparison of fiducial-based and CBCT image-
guidance during prostate radiotherapy 
 
There have not been any head-to-head dosimetric comparisons between 
patients treated with fiducial-based and CBCT-based IGRT. However, the 
correlation of shifts has been assessed in previous studies. In general, 
there is poor correlation particularly in the supero-inferior and antero-
posterior directions. 
 
On assessment of shifts, automatic grey-value matching on CBCT has 
been found to be different to fiducial matching (Shi et al., 2011). There 
was minimal difference along the lateral direction, with a mean of -0.02 cm 
(SD 0.13 cm). However, there were large discrepancies along the 
superior-inferior and anterior-posterior direction alignments. On the 
supero-inferior direction there was a mean difference of 0.55 cm (SD 0.48 
cm). In the anterior-posterior direction the mean difference was 0.31 cm 
(SD 0.43 cm). 
 
There is also some published work on the correlation of the shifts obtained 
by manual CBCT soft tissue matching and fiducial matching. Barney et al. 
found that there were clinically relevant differences between the shifts 
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using the different IGRT techniques. There was a mean difference in shifts 
of more than 3 mm in two out of three dimensions (Barney et al., 2011).  
 
Moseley et al. found that the shifts with manual soft tissue matching using 
CBCT was comparable to standard fiducial matching with portal imaging, 
in terms of the correlation of left-right shifts, but there was weaker 
correlation in the other dimensions (Moseley et al., 2007). The Pearson 
correlation coefficient was 0.90, 0.49 and 0.51 in the left-right, antero-
posterior and supero-inferior directions. One postulated reason was poorer 
observer demarcation of the apex of the prostate and the bladder-prostate 
interface on CT. There was no delineation of target organs undertaken in 
the study so this hypothesis could not be tested any further. 
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1.7 Overview of CBCT technology 
 
Cone beam CT uses a cone-shaped beam emitted from the x-ray source 
(Fig. 2) compared to a fan-shaped beam emitted from a diagnostic CT 
machine. The volume is reconstructed from the volume projections 
received by a 2-D detector using a circular motion around the target. This 
is in contrast to the slice-by-slice acquisition and 1-D detector used in 
conventional CT. The x-rays are received onto a flat-panel detector for 
reconstruction. 
 
Fig. 2. Comparison of fan beam and cone-beam CT imaging 
technique 
(Sukovic, 2003) 
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Cone beam technology utilizes x-rays more efficiently, so lower heat 
capacity x-ray tubes can be used. It allows for the use of smaller and less 
expensive x-ray components than fan-beam CT. Therefore, the technology 
lends itself to miniaturization for use in conjunction with a linear 
accelerator. The cone beam CT data can be referenced directly to the 
treatment coordinates as a result of such incorporation. 
 
It has been adopted by a number of manufacturers in image-guidance 
packages such as the Varian Trilogy®, Elekta Synergy® (Fig. 3) and 
Siemens Artiste® systems. Comparison of the main CBCT systems from 
the different manufacturers has shown that they have comparable image 
quality (Chan et al., 2011). 
 
Megavoltage (MV) CBCT is less widely available. MV CBCT is 
predominantly used in conjunction with helical tomotherapy (Ruchala et 
al., 1999), although it has been investigated with standard linear 
accelerators (Pouliot et al., 2005). Due to the physical characteristics of 
MV x-ray beams, the achievable image quality is limited. 
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Fig. 3. Elekta© CBCT on-board imager used in study 
 
The length and width of the x-ray field scanned during the cone beam CT 
imaging can be varied. The field of view refers to the width of the x-ray 
field to be scanned. In the smallest setting, the field is centred on the 
patient. In the larger settings, the beam is offset as shown in Fig. 4, to 
allow larger patient diameters to be scanned (Lehmann et al., 2007). 
There are also limited settings to adjust the length of field. The settings are 
chosen to achieve the imaging objective while minimizing dose to the 
patient. 
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Fig. 4. Field of view settings in kV CBCT imager 
 
A bow-tie filter (Fig. 5) is often used between the CBCT x-ray source and 
the patient. This functions as a compensator to modulate fluence and 
reduce scatter. It results in reduced skin dose and improved image quality, 
in particular image uniformity and low-contrast detectability (Mail et al., 
2009). 
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Fig. 5. CBCT bowtie filter  
a) External view of filter cassette b) Profile view in both dimensions c) 3-D 
representation.  (Downes et al., 2009) 
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1.8 Quality of CBCT imaging 
 
CBCT machines operate with lower energy than diagnostic machines to 
reduce exposure dose. This results in a lower signal to noise ratio. Scatter 
is a result of the larger detector area, and can result in streaking and lower 
soft-tissue tissue contrast. Other types of artefact include extinction 
artefacts, beam hardening artefacts, aliasing artefact, ring artefact and 
motion artefact (Schulze et al., 2011).  
 
Due to the above reasons, imaging on CBCT is of poorer quality than 
diagnostic CT. Phantom studies have shown that key imaging 
characteristics such as low-contrast visibility, spatial resolution, uniformity 
and image noise are all inferior for CBCT compared to diagnostic CT 
(Stock et al., 2009). 
 
The difference in image quality between CBCT and planning CT is 
demonstrated in Figs. 6 and 7 below. These show axial slices of a patient 
due to have prostate radiotherapy, and are taken at comparable levels. 
The soft tissue contrast is clearly lower in the CBCT compared to the 
planning CT. Nevertheless, the image quality is sufficient for organ 
contouring on a suitable high-resolution display. 
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However, kV CBCT imaging has better image quality than MVCT images 
(Varadhan et al., 2009). They quantified soft tissue contrast between kV 
CBCT and MVCT using three parameters – 3D low-contrast visibility, 3D 
image uniformity and 3D spatial resolution. On each of those image quality 
parameters kV CBCT performed better than MVCT. In their study, in terms 
of 3D spatial resolution, kV CBCT was even equivalent to standard kV CT. 
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Fig. 6. Axial image from pelvic planning CT 
Bladder (orange), Prostate (yellow), Rectum (red) 
 
Fig. 7. Axial image from CBCT scan  
Bladder (blue), Prostate (yellow), Rectum (magenta) 
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1.9 Dose calculation challenges 
 
Dose calculation on CBCT is limited mainly by non-comparability of CT 
density units (Yang et al., 2007). There are wide variations in CT density 
units in comparison to the planning CT scan, with the range of density 
being less in the cone beam CT. Radiotherapy treatment planning system 
algorithms depend on the electron density variations in the CT scan which 
can be calibrated from Hounsfield units in a standard planning CT scan.  
 
The differences in CT density units in cone beam CT lead to inaccuracies 
in dose calculation, unless corrective strategies are used. Some 
investigators have attempted to develop algorithms to enhance CBCT 
quality (Lou et al., 2013, Marchant et al., 2008), but dose calculation on 
these models have not been validated. 
 
There are two main approaches to calculate dose on CBCT. The first 
approach is the use of CBCT calibration tables. However, this is 
dependent on CBCT scanner, image acquisition parameters, body site 
and phantom used. Errors have been reported to be in the range of 1-3% 
with phantoms (Fotina et al., 2012). However, other investigators have 
reported errors of up to 10% with phantom-based calibration for the pelvic 
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site (Richter et al., 2008), and have recommended patient group-specific 
calibration tables.  
 
The other problem is that pixel values in CBCT systems can vary with the 
current-time product (mAs) setting for the x-ray tube. This is particularly 
seen with the Elekta XVI system (Kamath et al., 2011). This means that a 
single constant calibration factor cannot be applied for each site and 
patient. 
 
The second dose calculation approach is through the use of density-
override on CBCT. This could be done in two ways. The first method is the 
replacement of CBCT densities by standard densities for air, water and 
bone (Fotina et al., 2012). Alternatively, a region of interest (ROI) mapping 
method could be used where the tissue densities for each of the 
surrounding areas are mapped from the planning CT on to the CBCT (Hu 
et al., 2010, Fotina et al., 2012). However, this is particularly time-intensive 
as all surrounding organs have to be contoured and tissue densities 
replaced by those from the planning CT scan.  
 
My hypothesis for the initial phase was that density-override may not be 
required when calculating treatment dose in multi-field intensity-modulated 
radiotherapy (IMRT) to the prostate, particularly when 7 fields are used. In 
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such an instance, the main influence on dose change will be organ 
movement in relation to the high-dose field, rather than minor variations in 
tissue density of surrounding organs.  
 
The hypothesis is supported by previous prostate dosimetric studies 
(Orton and Tomé, 2004, Schulze et al., 2009). I therefore evaluated a 
method using kV CBCT contours on the planning CT, and compared this 
to the density-override method.  
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1.10 Previous CBCT dosimetric studies 
 
One of the initial dosimetric studies in prostate IGRT was done by 
Kupelian et al (Kupelian et al., 2006). They investigated the effects of 
organ motion during prostate radiotherapy. They had a relatively small 
cohort of 10 patients who underwent helical tomotherapy using implanted 
fiducials for image guidance. Patients were treated with a dose of 78 Gy in 
39 fractions, and a total of 390 megavoltage CT (MVCT) scans were 
available.  
 
Manual contouring was stated to have been performed on each MVCT 
scan, although the authors have not commented on the image quality of 
the megavoltage scans. Dose calculation was performed directly on the 
MVCT scan and dosimetric parameters reported were the D95 for the 
prostate and D2cc for the rectum. They found that there was insignificant 
variation in delivered dose to the prostate. The dose delivered to the 
prostate per fraction was 2.02 +/- 0.04 Gy. There were however large 
fluctuations in dose to rectum due to volume changes. 
 
The strength of this study was the availability of a complete set of CT 
images for the whole course of radiotherapy. Limitations of this study 
include the use of MVCT scans which have poorer image quality due to 
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the intrinsic characteristics of megavoltage energy. The MVCT scans did 
not fully encompass the bladder in some cases, leading to unreliability of 
the dose-volume parameters for the rectum and bladder in those 
instances. The small sample size meant that assessing predictive factors 
was difficult. The MVCT scans were not used for image guidance, so the 
study reflects on the use of fiducials for image guidance. The technique of 
tomotherapy that was used for radiotherapy delivery is also not widely 
used. 
 
Hammoud et al. (Hammoud et al., 2008) evaluated PTV margins using 
141 kV CBCT scans from 5 patients having prostate radiotherapy. They 
evaluated a 10/6 mm and 5/3 mm anisotropic margin, with a smaller 
margin posteriorly. They found that both margins allowed doses within 2% 
of the planned dose. The smaller margin allowed 30-50% sparing of high-
dose region in the rectum and bladder, although seminal vesicle coverage 
was reduced with a 5/3 mm margin. 
 
A major weakness of the Hammoud study was the small number of 
patients. In addition, only 72% of CBCTs could be used due to poor image 
quality in the rest. Although the patients had daily CBCT scans for 
research purposes, actual treatment verification and shifts were done 
using kV portal images. Therefore, the study could not assess the utility of 
the CBCT technique for imaging practice or assess the optimal frequency 
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of imaging. The dose calculation technique on CBCT was not described in 
detail. It appeared to be directly calculated on the CBCT using the 
treatment planning system, with no mention of a calibration table. 
 
A more recent study evaluated both dose distributions and margin 
reduction in 18 patients with who were treated with daily CBCT verification 
(Maund et al., 2014). Manual contouring of the prostate CTV and rectum 
was done by a single oncologist. Dose distributions were calculated using 
the cone beam contours transposed on the planned dose distribution, 
although the method used has not been described in any more detail. The 
investigators went on to evaluate biological parameters such as tumour 
control probability (TCP) and normal tissue complication probability 
(NTCP).  
 
Maund et al. found that there was no loss of TCP when plans with a 5-mm 
margin were re-optimized using 4 mm and 3 mm margins. Margin 
reduction was associated with a statistically significant reduction in rectal 
NTCP. The NTCP reduction was only 5% with a reduction in margin of 1 
mm. However, if a 2-mm margin reduction was used, there was a 36% 
reduction in NTCP. 
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The strengths of the study include the high quality of the imaging, allowing 
contouring of structures on all the included images. NTCP was calculated 
based on the validated Lyman-Kutcher-Burman model. 
 
The study cohort was small as only one CBCT per week was actually 
included in the analysis. As a result, the study could not be representative 
of the actual dose received throughout the course of radiotherapy. In 
particular, random variation in organ position cannot be assessed if only 
weekly CBCTs are analysed. The dose calculation technique was not 
specified in detail and no validation results were reported. Cumulative 
dose-volume histogram (DVH) curves were calculated by simple 
summation of the curves for seven fractions for each patient. TCP for the 
prostate and NTCP for the rectum were therefore not based on a voxel-
based cumulative distribution.  
 
A more recent study by Gill et al. evaluated PTV margins using daily 
CBCTs (Gill et al., 2015). They did not evaluate CBCT protocols. It was a 
retrospective study of five patients treated with hypofractionated 
radiotherapy 70 Gy in 28 fractions. Patients were treated with daily CBCT 
verification so a total sample size of 140 CBCT were available. Margins of 
1, 3, 5, and 7 mm were used to created separate plans and dosimetric 
analysis carried out. 
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Gill et al. used a CBCT calibration chart methodology for dose calculation. 
They found that the actual cumulative CTVs V100% were 96.55% ± 
2.94%, 99.49% ± 1.36%, 99.98% ± 0.26%, and 99.99% ± 0.05% for 1, 3, 
5, and 7 mm uniform PTV margins, respectively. Delivered bladder and 
rectum doses were different to the planned doses, with the magnitude of 
differences increasing with PTV margin. Their conclusion was that when 
daily CBCT was used for soft-tissue alignment of the prostate, a 3 mm 
PTV margin allowed for CTV to be covered for 99% of cases. The main 
limitation of the study was the small sample size of five patients. 
 
In summary, there are some dosimetric studies which have looked at the 
use of cone beam CT in prostate IGRT. However, there are significant 
weaknesses in these studies. Most studies did not evaluate daily CBCTs. 
Even in the single margin comparison study by Gill et al. which looked at 
daily CBCT, the number of patients was small. There remains no 
consensus on the optimum protocol for CBCT use in prostate 
radiotherapy. There is also no robust dosimetric validation of margin 
reduction with daily CBCT. 
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1.11 Study Objectives 
 
The overall objectives of this MD(Res) project were: 
1. To survey the current practice of image-guided radiotherapy for 
prostate cancer in the United Kingdom. 
2. To validate a practical dose calculation strategy on cone beam CT 
3. To assess the effects of CBCT verification imaging frequency on 
the actual dose delivered to the target volume and organs at risk 
during a course of image-guided radiotherapy (IGRT) for prostate 
cancer. 
4. To compare the dosimetric effects of reduction of CTV-PTV margin 
with daily imaging. 
  
49 
 
Chapter 2. Survey of current IGRT practice in the 
UK  
 
2.1 Background for IGRT survey 
 
Image-guided radiotherapy (IGRT) has become the standard of care for 
delivery of radiation treatment for prostate cancer. In its broadest 
definition, it encompasses a wide range of techniques ranging from simple 
visual checks to advanced techniques incorporating specialist imaging. 
The clinical benefit of using advanced IGRT in prostate cancer has been 
demonstrated in retrospective studies (Zelefsky et al., 2012, Gill et al., 
2011) which used fiducial marker techniques.  
 
In the United Kingdom (UK), the need for advanced verification techniques 
was recognized by the National Radiotherapy Action Group in 2007 
(Department of Health, 2007). They recommended that all new and 
replacement radiotherapy machines should have image-guided adaptive 
radiotherapy capability. The 2008 RCR report ‘On target: ensuring 
geometric accuracy in radiotherapy’ provided guidelines on verification for 
tumour sites including prostate (Royal College of Radiologists et al., 
2008). Further guidance on the use of IGRT was provided by the National 
Radiotherapy Implementation Group (NRIG) in 2012 (National 
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Radiotherapy Implementation Group, 2012). A national program has also 
been in place to provide dedicated clinical support for IGRT 
implementation (Society of Radiographers, 2013). 
 
A survey on the use of advanced radiotherapy technology in the UK was 
done in 2008 (Mayles and Radiotherapy Development, 2010). It 
demonstrated that there was limited availability of IGRT facilities, with only 
26 of 50 centres even having kilovoltage imaging capability. Lack of 
equipment was also the main reason cited by centres not carrying out 
IGRT. Online MV imaging was the main mode of prostate IGRT, with 50% 
of centres using this verification technique. Since the 2008 survey, there 
have been improvements in radiotherapy equipment in the UK. 87% of 
current linear accelerators are less than 10 years old, according to the 
National Radiotherapy Equipment Survey (National Clinical Analysis and 
Specialized Applications Team, 2011). The data from this 2010 survey 
also shows that 23% of installed machines have 3D imaging capability.  
 
The purpose of this survey was to evaluate the current status of prostate 
IGRT practice in the UK. In particular, it sought to identify the main 
verification strategies to be compared in the dosimetric analysis. 
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2.2 Survey methodology 
 
59 NHS radiotherapy centres were identified from the 2012 RCR Clinical 
Oncology UK Workforce Report (The Royal College of Radiologists, 
2013). Five private radiotherapy provider networks were also contacted. 
Centres were invited to the survey individually by phone, and respondents 
were identified by discussion with radiotherapy service managers. The 
survey was published using Opinio software, with online input of data. The 
survey was carried out from March 1, 2014 – April 30, 2014. An 
amendment to clarify one survey question was sent to all centres. Two 
reminders were sent to all centres which had not completed the survey. 
 
The pre-tested semi-structured survey questionnaire tool had 23 questions 
on radical prostate radiotherapy (Appendix 1). Post-prostatectomy 
radiotherapy was not evaluated in this survey. Survey questions covered 
details of patient preparation, use of fiducial markers, treatment planning 
system, radiotherapy dose/fractionation, type of verification imaging and 
correction strategies. Free text fields were also provided to capture 
additional data on variations in protocols. 
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2.3 Survey results 
 
50 NHS centres and three private radiotherapy providers responded giving 
an overall response rate was 83%. The survey was completed by 
physicists, radiotherapy dosimetrists, radiotherapy superintendents and 
specialist radiographers.  
 
Patient preparation 
 
There was a wide variation in bowel preparation protocols for prostate 
radiotherapy between centres. Daily micro-enemas (44%) and dietary 
information (35%) were the most common strategies used. Some centres 
reported using micro-enemas daily for the first 9-15 fractions followed by 
laxatives only if required. Five centres (9%) reported no fixed bowel 
preparation protocol.  
 
The majority of centres had a bladder preparation protocol with the patient 
drinking a specified volume of water prior to treatment. The volume given 
ranged from 300 – 500 ml, followed by a 20-60 minutes’ interval before 
radiotherapy treatment. Two centres used an empty bladder protocol, with 
one of these treating patients in the prone position. 
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Fiducial markers 
 
30 centres (55%) did not use fiducial markers for any patients. 12 centres 
(22%) used fiducial markers for all prostate radiotherapy patients and nine 
centres (16%) used markers for selected patients. The availability of 
marker insertion slots was cited as a limiting factor.  
 
In centres which used fiducial markers, the procedure was usually 
performed by a consultant urologist (43%). In 17% of centres an 
oncologist inserted the markers, while radiologists performed the 
procedure in 9%. Specialist nurses and specialist radiographers were also 
performing fiducial marker insertion (30%).  
 
The majority of centres used three markers, but one centre reported using 
two markers per patient. One centre also reported the use of prostate-
rectum spacers to reduce dose to rectum. 
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Radiotherapy planning and delivery 
 
There is widespread use of advanced planning and delivery techniques for 
prostate radiotherapy. 23 (42%) centres used intensity-modulated 
radiotherapy (IMRT) for all radical prostate radiotherapy patients, and a 
further 16 (29%) centres used IMRT for at least 50% of their prostate 
patients. A variety of advanced delivery systems were used (Table 1), with 
some centres using different modalities for specific prostate cancer patient 
groups.  
 
Table 1. Radical prostate cancer radiotherapy – external beam 
treatment delivery systems 
 
Radiotherapy delivery system Number of centres (%) 
Volumetric modulated arc 
radiotherapy 
34 (64%) 
Static beam IMRT 31 (58%) 
3-4 field conformal radiotherapy 29 (55%) 
Tomotherapy 5 (9%) 
Cyberknife 1 (2%) 
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Dose-fractionation regimens 
 
The most commonly used external beam dose-fractionation regimen was 
74 Gy/37# (Table 2). Dose escalation to 78 Gy or by using a HDR 
brachytherapy boost was carried out in only 6% of centres in this survey. 
Hypofractionated regimes were used in 24% of centres. Case selection 
criteria for dose-fractionation regimes were not assessed in this survey. 
 
Table 2. Dose-fractionation regimens for external beam 
treatment in radical prostate radiotherapy 
 
Dose-fractionation regime Number of centres (%) 
46 Gy to pelvis + HDR prostate 
boost 
1 (2%) 
78 Gy/39# 2 (4%) 
74 Gy/37# 49 (89%) 
60 Gy/20# 8 (16%) 
57 Gy/19# 3 (6%) 
64 Gy/32# 2 (4%) 
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Verification imaging 
 
The main verification imaging type used in radical prostate radiotherapy 
was cone beam CT (CBCT) with soft tissue matching (Fig. 8), used in 35 
centres (64%). 16 centres (29%) used fiducial markers in combination with 
imaging. This was usually in conjunction with KV imaging but seven 
centres used fiducial markers and CBCT. 5 centres (9%) used planar 
imaging only (3 portal MV, 2 portal KV). None of the centres reported 
using ultrasound for routine verification imaging. 
 
Fig. 8. Type of verification imaging in radical prostate radiotherapy 
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The most common verification imaging frequency was daily (Fig. 9), used 
by 32 centres (60%). 24 centres (45%) used a day 1-3 followed by weekly 
schedule, and four centres (8%) used a day 1-5 followed by weekly 
schedule. A combination of schedules was used in some centres that 
changed to daily imaging if there was concern about patient setup. 60% of 
centres which used CBCT repeated imaging during a fraction and set up 
the patient again if required. 
 
 
Fig. 9. Frequency of verification imaging in radical prostate 
radiotherapy 
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Correction strategy 
 
A variety of correction strategies were described by centres. 41 centres 
(75%) stated they used an online correction strategy. 21 of these centres 
used a zero-tolerance protocol. However, 20 centres had an action level 
for online correction. The action level varied from 1-5 mm. Two centres 
reported using a combined online-offline protocol. 11 centres used an 
offline protocol (two with online imaging for part of protocol). 34 centres 
reported using a systematic correction, with a median threshold of 3 mm 
(range 1-6 mm). The median threshold for gross error setup correction 
was 10 mm (range 2-10 mm). 
 
Private sector IGRT practice 
 
In the three private sector providers who responded, all radical prostate 
radiotherapy was delivered with intensity-modulated radiotherapy. For 
image-guided radiotherapy, two providers used daily online CBCT soft 
tissue matching. The other provider used CBCT on day 1-3 and weekly, 
with daily online matching with fiducials and kV portal imaging on other 
days. Fiducial marker insertion was consultant-led in all cases. 
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2.4 Discussion of survey results 
 
This survey captures data on current prostate IGRT practice in the United 
Kingdom. The high response rate of 85% amongst NHS centres minimized 
non-response bias. There was a 60% response rate amongst private 
provider networks, providing an insight into the service offered by non-
NHS radiotherapy centres.  
 
There were a few limitations in this survey. I did not evaluate the margins 
used during generation of the planning target volume. While the CTV-PTV 
margin should be based on individual institution setup errors, it may be 
influenced by the type of IGRT available. This study also did not 
specifically evaluate pelvic lymph node irradiation, which may be 
associated with specific challenges in relation to image guidance. 
 
The high uptake of volumetric imaging for prostate IGRT shows a trend 
similar to that identified in surveys in the United States in 2009 (Simpson 
et al., 2010) and 2014 (Nabavizadeh et al., 2016). In the most recent 
survey done in the United States, 77% of IGRT for prostate radiotherapy 
was done using volumetric imaging, with 96% using daily imaging. They 
did not however find any relationship between frequency of imaging and 
the CTV-PTV margin employed by participating physicians.  
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There has been a clear improvement in utilization of advanced 
radiotherapy techniques in the UK, with a higher use of IMRT and 
advanced IGRT compared to previous UK surveys. However, there remain 
some inequities in provision of image guidance technology, with 5 NHS 
centres using planar imaging only. However, two of these centres 
specified that they were planning to introduce more advanced image-
guided treatment within the next few months. 
 
The majority of centres use a dose-fractionation regimen of 74 Gy/37#. A 
few centres have started to use dose escalation, in line with clinical trial 
results which show a benefit in progression-free survival (Kuban et al., 
2008, Al-Mamgani et al., 2008) . However, 2 centres reported the use of 
64 Gy/32#. This regimen has been shown to have lower toxicity, but lower 
progression-free survival (Dearnaley et al., 2014). With the widespread 
availability of advanced IGRT techniques, the use of dose escalation is 
likely to be better tolerated, and this lower dose regimen would not be 
considered standard of care in current practice. 
 
In this survey, the use of fiducial markers for radical prostate radiotherapy 
appears limited. This appears to be related to resource limitations for 
fiducial insertion and the widespread availability of non-invasive on-board 
imaging techniques. The ongoing CHHiP IGRT sub-study is evaluating the 
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clinical outcomes of IGRT using fiducial markers and reduced margins, 
and long-term results of this study are awaited.  
 
There are two main CBCT imaging frequency protocols currently in use in 
the UK. Over half the centres were using daily imaging, but many centres 
used a day 1-3 followed by weekly schedule. Daily online imaging has the 
best potential to correct for target position variation. However, concomitant 
pelvic dose of 1-2 Gy during a course of daily kV CBCT imaging (Sykes et 
al., 2013) should also be taken into consideration. Further research is 
required to determine the optimal schedule for CBCT verification. 
 
There is continuing progress in image-guided radiotherapy, with the 
development of prototype hybrid MRI-linear accelerators (Lagendijk et al., 
2008). However, this is still a research technology limited to a few centres 
in the UK. Further research is required on existing IGRT techniques to 
guide their optimum use. It would also be useful to incorporate details of 
IGRT technique into clinical trials to consolidate the evidence base for its 
use in prostate radiotherapy.  
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Chapter 3. Validation of dose calculation method  
 
3.1 Ethical considerations 
 
My study involved retrospective review of basic demographic and clinical 
information, radiotherapy plans and dosimetry data in Cancer Partners UK 
which is a private sector health care network. Institutional approval was 
granted by the Cancer Partners UK research review body.  
 
All patients were treated in line with standard institutional clinical protocols. 
Radiation exposures were governed by Ionising Radiation (Medical 
Exposure) Regulations 2000 (IRMER) (Department of Health, 2000). No 
additional treatments or radiation exposures were done as a result of my 
study.  
 
All patient data was anonymized and securely maintained only on a 
company network, in line with institutional data storage guidelines. The 
data management guidelines are compliant with the legislative provisions 
of the Data Protection Act 1998 (Great Britain, 1998). 
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3.2 Validation study - Material and Methods 
 
37 consecutive CBCT scans from a patient undergoing radical prostate 
radiotherapy with daily IGRT were included. The total dose delivered was 
74 Gy in 37 fractions using 7-field IMRT. The CBCT settings used were 
120 kV, 64 mA/frame, 40 ms/frame, a medium field of view (FOV), 15 cm 
scan length and half fan mode. A full 360-degree acquisition was used at 
180 degrees/minute. An amorphous silicon flat panel detector was used 
for detection. The maximum diameter for reconstruction was 410 mm with 
the medium FOV. All patients in this study had a medium FOV used. 
CBCT images were imported into the Pinnacle planning system and 
registration confirmed.  
 
The prostate, rectum, bladder and pelvic bones were manually contoured 
on each CBCT slice (Figs. 10, 11). Manual contouring was required as 
automatic contouring software in development by the manufacturer could 
not be used on CBCT due to the differences in CT density compared to 
standard diagnostic CT scans.  
 
At the time of this study, there were no commercial contouring packages 
which would accurately meet the needs of my investigation. Deformable 
image registration approaches have been attempted previously in 
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research settings but have achieved only modest results, with large 
proportions of unacceptable contours (Thor et al., 2011).  
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Fig. 10. Axial slice of CBCT showing contoured organs 
Bladder (blue), CTV (red), rectum (purple) 
 
Fig. 11. Sagittal slice of CBCT showing contoured organs 
Bladder (blue), CTV (red), rectum (purple) 
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CBCT contours were assigned to the planning CT and dose calculation 
performed using the planned treatment fields (Fig. 12). The background 
for the study technique was from previous prostate dosimetric studies 
(Orton and Tomé, 2004, Schulze et al., 2009). My hypothesis was that 
when IMRT with 7 fields is used, the key determinant of dosimetric 
changes would be organ movement. 
 
 
Fig. 12. Schematic of study method 
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A region of interest mapping approach was used for the comparator 
density-override method, as described by Fotina et al (Fotina et al., 2012). 
The same contours were used on CBCT scans, with CT densities for 
surrounding structures from planning CT (Fig. 13). 
 
Fig. 13. Schematic of density-override method 
 
Only the first 25 fractions could be used for the density-override method 
due to planning system capacity constraints. For the density-override 
technique, the dynamic planning feature of the Pinnacle treatment 
planning software was used. This added a series of CBCT for each 
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fraction cumulatively onto the treatment plan. The enormous number of 
CBCT images stored in each plan led to a progressive slowing of the 
planning software. At 25 fractions, the validation study had to be stopped 
for the density-override technique due to the system starting to ‘freeze’.  
 
3.2.1 Statistical tests 
 
Dosimetric parameters were compared using Pearson correlation for the 
first 25 fractions, using IBM® SPSS® statistical software. To assess 
agreement between the methods, a Bland-Altman plot was constructed by 
plotting the difference between results against the mean values. 95% 
confidence intervals for the difference were calculated to provide limits of 
agreement for the Bland-Altman plot.  
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3.3 Validation study - Results 
 
The mean difference between methods was 0.28% for the PTV V95 and 
0.64% for the rectal V50. There was excellent correlation between 
dosimetric results with CBCT contours on the planning CT, in comparison 
to the use of CBCT with density-override (Figs. 14, 15). The correlation 
was strongly statistically significant, with p < 0.001 in both cases (Table 3).  
 
Table 3. Correlation between methods 
 
 
 
 
 
 
 
Parameter Pearson correlation coefficient r p 
PTV V95 0.93 p < 0.001 
Rectal V50 0.98 p < 0.001 
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Fig. 14. Correlation between methods for PTV V95 
 
Fig. 15. Correlation between methods for rectal V50Gy 
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In addition to correlation, there appeared to be good agreement between 
the methods on plotting the trends of the values over the course of 
radiotherapy (Figs. 16, 17). Bland-Altman graphs were created to assess 
agreement statistically. The Bland-Altman analysis demonstrated low 
levels of bias and good agreement between the methods. All the 
measured points for PTV V95% fell between the 95% levels of agreement 
(Fig. 18). For the rectal V50Gy equivalent, 2 data points fell just outside 
the 95% level of agreement as can be seen in Fig. 19. 
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Fig. 16. PTV V95 – Comparison between study method and density-
override method 
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Fig. 17. Rectal dose – Comparison between study method vs density-
override method 
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Fig. 18. Bland-Altman plot for PTV dose – study method vs density-
override 
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Fig. 19. Bland-Altman plot for rectal dose – study method vs density-
override 
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3.3 Validation study - Discussion 
 
The validation study was an essential exercise at the start of this MD(Res) 
project. It was useful to develop study workflow and processes, in addition 
to establishing the validity of dose calculation on CBCT using our method. 
This was particularly important due to the large-scale data movement 
between multiple software systems in radiotherapy. 
 
The ROI mapping approach was chosen as a comparator based on my 
literature survey which showed that it gave the most consistent results for 
CBCT dose calculation. However, it was very time-intensive due to the 
need to outline multiple regions of interest for density replacement. As the 
number of contoured regions increased, there were increasing demands 
on processing power. This led to the system slowing down to critical 
levels, and the validation had to be stopped after 25 fractions for the ROI 
mapping method. Our study method proved to be much more resource-
effective, which is an advantage. 
 
A larger validation study would have been preferable. In retrospect, it 
might also have been preferable to do the validation study using random 
fractions of multiple subjects to evaluate inter-subject differences. 
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However, this would have limited our assessment of temporal changes 
during the course of radiotherapy, between the two methods. 
 
The Bland-Altman technique was chosen to assess agreement. This is 
because there are limitations to using Pearson correlation to assess 
agreement between measurements (Martin Bland and Altman, 1986). 
Correlation provides an indication of the strength of a relationship between 
two variables. As long as the two variables plotted against each other 
approximate a straight line, the correlation would be high. However, the 
values of the variables may be systematically different from each other 
despite high correlation. Therefore, Bland and Altman suggested the use 
of a graphical plot of agreement using the difference between 
measurements against the mean measurement. 
 
There was very good correlation and agreement between methods for key 
parameters chosen for target coverage and rectal dose. The limits of 
agreement are in line with the errors observed on other CBCT dose 
calculation methods.  The study also established the feasibility of using the 
study method with a streamlined and time-effective workflow. This is of 
relevance if the method is to be used for adaptive radiotherapy. 
Considering all of the above factors, the study method was selected for 
use in my dosimetric research. 
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Chapter 4. CBCT comparison with bone match 
verification 
 
4.1 CBCT comparison with bone match – materials and 
methods 
 
592 CBCT verification images from 14 patients who received radical 
prostate radiotherapy and had a complete CBCT dataset were analysed. 
All patients received a dose of 74 Gy in 37 fractions of 2 Gy using 7-field 
step-and-shoot IMRT.  
 
Daily online CBCT soft tissue match verification was done using the Elekta 
XVI system. The CBCT settings used were 120 kV, 64 mA/frame, 40 
ms/frame, a medium field of view (FOV), 15 cm scan length and half fan 
mode. A full 360-degree acquisition was used at 180 degrees/minute. An 
amorphous silicon flat panel detector was used for detection. The 
maximum diameter for reconstruction was 410 mm with the medium FOV. 
All patients in this study had a medium FOV used. 
 
A bone match verification strategy was used for the study comparison 
arm, with imaging on day 1-3 followed by weekly. Bone match results were 
79 
 
obtained using automated analysis of bony anatomy on CT. CBCT images 
were imported into the Pinnacle treatment planning system. CTV, bladder 
and rectum were contoured manually on each image.  
 
A 7-mm margin in all directions was used on the CTV to obtain the 
planning target volume. Soft tissue and bone match shifts were applied to 
each CBCT image. CBCT contours were overlaid on planning CT scan for 
dose-volume analysis. Dose-volume parameters were assessed for CTV, 
rectum and bladder. 
 
4.1.1 Statistical tests 
 
Statistical analysis was carried out on IBM® SPSS® version 22. Shapiro-
Wilk testing was carried out to assess normality of the difference between 
paired parameters (SHAPIRO and WILK, 1965). Means and standard 
errors of means were used to describe normally distributed variables. For 
variables which violated assumptions of normality, medians and ranges 
were used to describe the data. Related-sample Wilcoxon signed rank test 
was used to do non-parametric testing for CTV and PTV variables 
(Wilcoxon, 1945). Two-sided tests were conducted in all cases, with a 
level of statistical significance of 5%.  
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4.2 CBCT comparison with bone match - results 
 
There was improved target coverage with CBCT soft tissue matching in 
comparison to a bone match protocol. This effect was seen with both CTV 
V95% and CTV V98% (Fig. 20, 21) on fraction-by-fraction analysis. 
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Fig. 20. CTV V98 for daily CBCT protocol   
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Fig. 21. CTV V98 for bone match 
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Wilcoxon signed-rank test was used to compare non-parametric 
dosimetric thresholds for paired samples. There was a significant 
improvement in CTV coverage and reduction in rectal dose with daily 
online CBCT (Table 4). 
 
Table 4. Daily CBCT vs bone match 
 
Variable Daily CBCT 
protocol Median% 
(interquartile 
range) 
Bone match 
protocol Median% 
(interquartile 
range) 
Wilcoxon  
signed-rank 
test 
significance 
CTV V95 99.96 (0.13) 99.50 (1.12) p < 0.05 
CTV V98 98.42 (2.96) 97.12 (2.20) p < 0.05 
Rectal 
V50 
32.62 (9.53) 35.29 (11.69) p < 0.05 
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There were reductions in rectal V50Gy in 13/14 patients with a daily online 
CBCT verification strategy compared with a bone match protocol. The 
biggest reductions were observed in patients G and H who had relatively 
high V50Gy (Fig. 22).  
 
 
Fig. 22. Rectal V50Gy comparison – planned dose vs bone match 
protocol vs daily CBCT protocol 
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4.3. CBCT comparison with bone match – discussion 
 
This cohort demonstrated that use of a day 1-3 followed by weekly bone 
match protocol led to frequent drops in target coverage during the course 
of radiotherapy. The improved target coverage with CBCT may be due to 
both the additional frequency of imaging and the additional soft tissue 
detail allowing accurate target verification. 
 
This sub-study utilized automated cone beam CT bone matching. This is 
likely to be more accurate than portal imaging bone matching due to the 
better image quality. It is therefore likely that use of kV or MV portal 
imaging for bone match is likely to lead to even worse results in target 
coverage. 
 
It is reassuring that the rectal dose was also reduced by the use of cone 
beam CT soft tissue matching. The reductions in rectal dose were of 
relatively small magnitude for most patients. However, for the patients with 
the highest V50Gy at planned, CBCT matching appeared to provide most 
benefit in this cohort. 
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Chapter 5. CBCT protocol and margin comparison 
 
5.1 CBCT protocol and margin comparison – objectives 
 
1. To assess the effect of frequency of CBCT verification imaging on 
the dose-volume parameters of the target volume and organs at 
risk during a course of IGRT for prostate cancer. The study 
compares two established IGRT protocols: 
a. Daily CBCT imaging with online correction prior to every 
treatment fraction. 
b. CBCT imaging prior to fractions 1 to 3 and subsequently 
once weekly. Online corrections are applied prior to 
treatment for every fraction on which CBCT is carried out. 
Following the first three fractions the systematic error is 
calculated and a systematic setup correction applied for any 
error that is ≥ 0.5 cm. 
 
2. To assess the dosimetric impact of reducing the PTV margin, when 
daily online imaging is used. 
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5.2 CBCT protocol and margin comparison - materials and 
methods 
 
The null hypothesis for this stage of the project was that there is no 
difference between daily imaging and weekly imaging for prostate target 
coverage and organ at risk dose. 
 
844 CBCT verification images from 20 patients undergoing radical 
prostate radiotherapy were analysed retrospectively. Patients were treated 
between Feb 2012 and Aug 2013 for localized prostate cancer. Organ 
contouring on the planning computed tomography (CT) scan was carried 
out by the treating oncologist. The CTV included the prostate and base of 
seminal vesicles. A uniform margin of 7 mm around the CTV was used to 
generate the planning target volume (PTV). None of the patients had 
pelvic lymph node radiation. 
 
Treatment planning was carried out on Philips® Pinnacle3 software. The 
planning constraints used are listed in Table 4. ICRU 83 guidelines 
(Gregoire and Mackie, 2011) recommend the use of median dose D50, 
near max dose D2, near min dose D98 for the PTV during IMRT planning 
and reporting. However, these guidelines had not been implemented in the 
study centres at the time of initial planning of the study patients. The organ 
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at risk constraints are based on the UK prostate CHHiP clinical trial 
protocol. These constraints have been shown to lead to better rectal 
sparing than the MRC RT-01 trial constraints (South et al., 2008).  
 
Table 5. Radiotherapy planning constraints  
Organ Parameter Constraint 
CTV V95% 100% 
PTV V95% ≥98% 
Rectum 
V50Gy 
V60Gy 
V65Gy 
V70Gy 
V74Gy 
< 60% 
< 50% 
< 30% 
< 15% 
< 5% 
Bladder 
V50Gy 
V65Gy 
V74Gy 
< 50% (optimal) 
< 50% (mandatory) 
< 5% 
Small bowel V50Gy < 17cc 
Femoral heads V50Gy < 50% 
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Patients were treated supine with a comfortably full bladder and were all 
given dietary advice to minimize rectal distension. Laxatives were used 
only if required to manage constipation. All patients received a dose of 74 
Gy in 37 fractions over 7½ weeks using 7-field intensity-modulated 
radiotherapy (IMRT) delivered on the Elekta® linear accelerator platform. 
Early toxicity was assessed using the RTOG acute radiation morbidity 
scale (Cox et al., 1995). 
 
During treatment, patients had daily online CBCT soft tissue match 
verification using the Elekta XVI system. Concomitant dose from CBCT 
was measured using a Perspex phantom using the CT dose index (CTDIw) 
method (Murphy et al., 2007). 4 imagers were used in the study and the 
relevant CTDIw measurements are shown in Table 6.  
 
Imager CTDIw (mGy) 
1 25.2 
2 27.5 
3 27.6 
4 30.3 
 
Table 6. CTDIw measurements for CBCT imagers used in study 
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The CBCT settings used were 120 kV, 64 mA/frame, 40 ms/frame, a 
medium field of view (FOV), 15 cm scan length and half fan mode. A full 
360-degree acquisition was used at 180 degrees/minute. An amorphous 
silicon flat panel detector was used for detection. The maximum diameter 
for reconstruction was 410 mm with the medium FOV. All patients in this 
study had a medium FOV used. The F1 filter setting was used to 
incorporate an aluminium bowtie filter to reduce skin dose and improve 
image quality. An amorphous silicon flat panel detector was used for 
detection.  
 
The time required for CBCT review was assessed in a timing study for 92 
CBCT images across 3 centres. The mean acquisition time per CBCT was 
130 seconds (range 118 – 175 seconds). The mean time required for 
review by the treatment radiographer was 100 seconds (range 32 – 326 
seconds). The total additional time during treatment fractions was 232 
seconds (range 130 – 462 seconds).  
 
If the initial CBCT indicated a significant issue with anatomy (e.g. rectum 
too full or bladder too empty) the patient was taken off the bed and 
encouraged to visit the bathroom and walk around, after which they were 
setup again and CBCT carried out again prior to treatment. Online soft 
tissue match verification with a 0-cm action level was carried out by one 
treatment radiographer, and checked by a second treatment radiographer. 
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Radiographers were accredited for CBCT verification on completion of an 
in-house training package.  
 
All CBCT images were imported into the Pinnacle3 treatment planning 
system. Target volume and organs at risk were contoured manually on 
each CBCT image by a single investigator, and separately evaluated by 
the supervising radiation oncologist. Contouring of normal organs was 
based on the consensus RTOG contouring atlas (Gay et al., 2012). A 7-
mm margin in all directions was used around the CTV to obtain the PTV.  
 
Soft tissue match shifts were separately applied to each CBCT image. For 
the daily imaging protocol, the actual shifts were applied to every CBCT. 
For the weekly protocol, soft tissue match shifts were applied to imaging 
days and a systematic correction was applied to non-imaging days, where 
required. The average was taken from first three days and if any value 
was greater than 5mm then a systematic correction was applied for that 
direction.  
 
Systematic and random errors were calculated for the population 
according to standard calculation formulae (Royal College of Radiologists 
et al., 2008). First, the overall mean population set-up error (Mpop) was 
calculated using the formula:  
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Mpop = (m1+m2+m3+…. +mp) / P 
 
In this equation, m1, m2, m3…were the means for each individual patient, 
and P is the number of patients in the analysed group.  
 
The systematic error for the population (Σset-up) was defined as the 
standard deviations of the mean set-up error about the overall population 
mean (Mpop). The individual random error (σindividual) was defined as the 
standard deviation of the setup errors around the mean individual error 
(m). The population random error (σset-up) was the mean of all the random 
errors. 
 
The CBCT contours were superimposed on the planning CT scan for 
dose-volume analysis as described in the validation study methodology 
(section 3.2). The same contours were used for comparison of a daily 
online schedule with a protocol of day 1-3 followed by weekly imaging. For 
the margin comparison, plans were recalculated on Pinnacle with 3 mm 
and 5 mm margins all around the CTV. Dose calculation was done on 
Pinnacle3 version 9.6 using the collapsed cone convolution algorithm 
(Ahnesjo, 1989). 
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Dose-volume parameters were assessed for the PTV, CTV, rectum and 
bladder. As described above, our institution used a V95% threshold during 
treatment planning. Therefore, the PTV and CTV dose in the study was 
assessed using the V95%. A target value of 99% was chosen for the CTV 
V95% coverage, in line with the Stroom threshold for margin calculation 
(Stroom et al., 1999). The V98% was also assessed for the CTV as a 
more sensitive indicator of high dose coverage. The V50Gy, V65Gy, mean 
dose and D2cc were compared for the rectum. The selection of rectal 
dose parameters to be reported was based on published data which have 
identified these thresholds as relevant to toxicity (Chennupati et al., 2014). 
The V65Gy and mean dose were compared for the bladder.   
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5.1.1 Statistical methods - sample size calculation 
 
Preliminary sample size estimation was carried out prior to data collection. 
Sample size calculation was done using the open-source software 
G*Power© version 3.1.9.2. Rectal toxicity reduction was chosen as the 
primary outcome for sample size estimation purposes. I used an estimated 
reduction of 1 Gy in mean rectal dose when daily imaging was used. This 
was based on estimates of potential benefit with online adaptive 
radiotherapy obtained from a simulation study (Schulze et al., 2009).  
 
I used an alpha value of 0.05 to minimize type 1 error and a beta value of 
0.95 to minimize type 2 errors. The estimated total sample size for a 
paired t-test approach was 16. A sample size of 20 was therefore utilized 
in my study to provide a further margin of power and accuracy. 
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5.1.2 Statistical methods - analysis of results 
 
Statistical analysis was carried out on IBM® SPSS® version 22. Shapiro-
Wilk testing was carried out to assess normality of the difference between 
paired parameters. Means and standard errors of means were used to 
describe normally distributed variables. For variables which violated 
assumptions of normality, medians and ranges were used to describe the 
data. The Hodges-Lehman estimate (Hodges and Lehmann, 1963) was 
used to assess the difference between medians for these variables. 
 
In the protocol comparison, related-sample Wilcoxon signed rank test was 
used to do non-parametric testing for CTV and PTV variables (Wilcoxon, 
1945). Paired t test was used for parametric testing of rectal and bladder 
variables which were normally distributed.  
 
For the comparison of the three PTV margins, Friedman’s test (Friedman, 
1937) with Bonferroni correction was carried out for CTV V95% as it was 
not normally distributed. Repeated measures ANOVA with Bonferroni 
correction was used for the margin comparison of the parametric rectal 
and bladder dosimetric results. Two-sided tests were conducted in all 
cases, with a level of statistical significance of 5%.  
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5.3 CBCT Protocol comparison - Results 
 
All study patients had localized prostate adenocarcinoma (stage T1-2 N0 
M0) with histological confirmation. Patients tolerated the radiotherapy 
treatment protocol well, with minimal acute toxicity. There was no RTOG 
Grade 3 or 4 rectal or bladder toxicity during treatment.  
 
844 CBCT scans were included in the study. The population setup errors 
were calculated using shifts from the daily imaging protocol. The 
population mean setup error was 0.01 cm (left-right), 0.05 cm (supero-
inferior) and -0.13 cm (antero-posterior). The population systematic error 
(Σ) was 0.27 cm (left-right), 0.15 cm (supero-inferior) and 0.38 cm (antero-
posterior). The population random error (σ) was 0.23 cm (left-right), 0.17 
cm (supero-inferior) and 0.31 cm (antero-posterior). The setup errors in 
my investigation are in line with a previously published CBCT verification 
imaging series (Mayyas et al., 2013). 
 
The median number of CBCT scans per patient was 43 (range 37-48). The 
most common reason for re-imaging was excessive rectal gas. The quality 
of the CBCT images was adequate in the clear majority of cases, allowing 
contouring of the prostate, rectum and bladder. Artefact due to rectal gas 
affected contouring of the prostate and rectum in only 5 fractions in the 
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entire cohort (0.6%). In each of these cases, the patients went on to have 
a 2nd CBCT for the fraction, which was contoured to evaluate the daily 
treatment schedule. In 6 out of 20 patients, the dome of the bladder was 
not included in the CBCT scan volume. CTV volume on cone beam CT 
showed minimal variation from the original CTV. The mean change in CTV 
volume from the planning CT was 0.2% (range –1.9% to +2.1%) (Fig. 23). 
 
 
Fig. 23. Mean Rectal and CTV volume change from planning CT 
Blue – Rectal volume, Red – CTV volume 
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Rectal volume showed major fluctuations from the volume on the planning 
CT scan, throughout the course of treatment. The mean rectal volume 
during treatment was higher than the planning CT volume in the majority 
of cases. The mean change in rectal volume from planning volume was 
12.8% (range -21.4% to 66.5%). However, there were increases in rectal 
volume up to 180% of planning volume during treatment (Fig. 24). 
 
Fig. 24. Change in mean treatment volumes from volume on planning 
CT scan 
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There was a moderate correlation between the rectal volume on planning 
CT scan and the range of rectal volume variation on CBCTs during 
treatment (Pearson’s R = 0.46, p < 0.05). However, high rectal volumes on 
the initial planning CT scan were not associated with a reduction in CTV 
coverage during treatment, both in the weekly (Spearman’s rho 0.1, p > 
0.05) and daily (Spearman’s rho -0.05, p > 0.05) CBCT groups (Fig. 25). 
 
 
Fig. 25. CTV V98% variation with rectal volume on planning scan 
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There were improvements in PTV and CTV coverage with daily imaging 
compared to weekly imaging (Table 7). The There was a 3% improvement 
in PTV V95% and a 1% improvement in CTV V98% (Hodges-Lehman 
estimates of difference between medians, p < 0.001 on Wilcoxon sign rank 
testing).  
 
Table 7. Median target volume coverage parameters – daily 
online vs weekly online verification 
Parameter Daily Online (IQR) Weekly Online (IQR) p 
PTV V95 / % 94.36 (93.33 – 95.51) 90.97 (88.68 – 92.03) p < 0.001* 
CTV V95 / % 99.98 (99.92 – 100.00) 99.74 (98.96 – 99.82) p < 0.001* 
CTV V98 / % 98.90 (96.80 – 99.70) 97.65 (95.94 – 98.53) p < 0.001* 
n = 20, PTV – Planning target volume, CTV – Clinical target volume, IQR – 
Interquartile range 
*Related-sample Wilcoxon signed-rank test, significant at p < 0.05 
 
90% of patients had improvement in prostate target coverage with daily 
online imaging in comparison to weekly online imaging. Daily online 
imaging was the best verification protocol, with a median of 37 fractions 
(out of 37) achieving CTV coverage with daily imaging compared with 34 
fractions with the day 1-3 then weekly online protocol (Fig. 26). 
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Fig. 26. CTV coverage – Comparison of verification imaging 
protocols 
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80% of patients had a reduction in rectal dose with the daily imaging 
protocol, in comparison to the weekly protocol. On dosimetric analysis, 
there was a 1.12 Gy reduction in mean rectal dose (Table 8). There was 
no statistically significant difference in the high-dose region parameter 
D2cc. There were no significant differences in bladder dose, with the 
V65Gy and mean bladder dose at low levels with both protocols. 
 
Table 8. Mean pelvic organ at risk parameters – daily online vs 
weekly online verification 
Parameter Daily 
Online 
Weekly 
Online 
Differenc
e:  
Daily - 
Weekly 
SEM p 
Rectal V50Gy / % 32.48 34.96 -2.49 0.99 p < 0.05† 
Mean rectal dose / 
Gy 
36.56 37.68 -1.12 0.52 p < 0.05† 
Rectum D2cc/Gy 73.37 73.35 0.02 0.22 NS† 
Bladder V65Gy / % 10.32 9.90 0.42 0.30 NS† 
Mean bladder 
dose / Gy 
23.13 22.82 0.31 0.28 NS† 
n = 20, SEM – Standard error of mean, NS – Not significant 
†Paired t test, significant at p < 0.05 
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There were 82 radiotherapy fractions where additional CBCT imaging was 
performed during daily imaging (excluding the first 3 fractions). The daily 
imaging protocol led to detection of rectal distension and under-filling of 
the bladder. There was a 17% mean reduction in rectal volume and 52% 
mean increase in bladder volume in fractions where CBCT imaging was 
repeated after review. The CTV V98 increased from 92.4% to 97.5% in 
these fractions.  
 
The magnitude of benefit of daily imaging for a patient could not be 
predicted by characteristics on the planning CT scan. No significant 
univariate correlations were identified between the differences in CTV 
coverage with factors such as rectal volume at planning, mean rectal 
volume over first 3 fractions, mean treatment rectal volume, CTV volume, 
initial bladder volume and mean treatment bladder volume.  
 
On unpaired analysis of daily imaging data, there was an association 
between an increased rectal volume and low bladder volume with a 
reduction in CTV V98%. (Fig. 27). However, this association was not 
statistically significant on a mixed model when inter-patient variation was 
incorporated into the model (Fig. 28).  
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Fig. 27. CTV V98 variation with rectal and bladder volume (unpaired 
analysis) 
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Fig. 28. CTV V98 variation with rectal volume (cases labelled) 
 
I investigated the relationship between rectal volume on each fraction with 
the rectal dose. For rectal V50Gy, there was a modest negative correlation 
with rectal volume (Spearman’s rho -0.46, p < 0.001) (Fig. 29). The 
correlation was slightly less with mean rectal dose (Spearman’s rho -0.40, 
p < 0.001). There was no statistically significant association on linear 
mixed model testing for rectal V50Gy (F 1.44, p = 0.42). 
 
106 
 
 
 
Fig. 29. Rectal V50Gy variation with rectal volume for all fractions 
with daily imaging  
(separate cases colour-labelled; polynomial trend line) 
 
Bladder V65Gy was moderately correlated with bladder volume 
(Spearman’s rho -0.66, p < 0.001). For mean bladder dose, there was a 
strong negative correlation of mean bladder dose with bladder volume 
(Spearman’s rho -0.73, p < 0.001) (Fig. 30). This relationship remained 
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statistically significant on linear mixed model testing for mean bladder 
dose (F 6.56, p = 0.038) when interpatient variation was incorporated. 
 
Fig. 30. Mean bladder dose variation with bladder volume for all 
fractions with daily imaging  
(separate cases colour-labelled; polynomial trend line) 
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5.4 Protocol comparison case studies 
 
I evaluated individual patient rectal and bladder dose-volume relationships 
for 2 cases to look for trends or predictive factors. These 2 cases were 
intentionally selected as they showed extremes of systematic or random 
geographic miss during weekly imaging. 
 
5.3.1 Case 1 
 
Patient 3 had 6 fractions with inadequate coverage using the day 1-3 then 
weekly online protocol, compared with 1 fraction for the daily online 
protocol. 3-D dose reconstructions were performed using the 95% isodose 
as a threshold. The difference in coverage for fraction 23 is illustrated in 
axial and sagittal images in Fig 31 - 32 (weekly online) compared to Fig. 
33 - 34 (daily online). As can be seen, the superior portion of the CTV 
including the base of the seminal vesicles is outside of the 95% isodose 
immediately prior to treatment.  
 
In this patient, there was a systematic geographic miss with this area 
outside the threshold on all 6 fractions on the weekly schedule (Fig. 31-
32). This could potentially result in failure of local control if the tumour was 
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situated at the base of the prostate. Therefore, the clinical impact of daily 
imaging is clearly high in this situation. 
 
The improvement in target coverage for this patient was associated with a 
reduction in dose to rectum. The rectum V50Gy was 37.6% with the 
weekly online simulation compared to 32.7% with the daily online 
treatment regimen. The mean rectal dose was reduced from 40.5 Gy to 
38.1 Gy. There was minimal difference in the rectum D2cc with values of 
74.0 Gy with both regimens. There was a slight increase in bladder dose 
with the daily regimen. However, the higher bladder V65Gy of 12.2% with 
daily imaging compared to 10.6% with the weekly were both well below 
the risk thresholds for the organ. 
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Fig. 31. Case 1: Antero-posterior projection of 95% isodose for CTV 
with weekly imaging 
Fraction 6 – 95% Isodose (blue), CTV (red) 
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Fig. 32. Case 1: Lateral projection of 95% isodose for CTV with 
weekly imaging 
Fraction 6 – 95% Isodose (blue), CTV (red) 
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Fig. 33. Case 1: Antero-posterior projection of 95% isodose for CTV 
with daily imaging 
Fraction 6 – 95% Isodose (blue), CTV (red) 
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Fig. 34. Case 1: Lateral projection of 95% isodose for CTV with daily 
imaging 
Fraction 6 – 95% Isodose (blue), CTV (red) 
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Dose-volume histograms (DVH) for the CTV (in red, extreme right of 
chart), rectum (purple) and bladder (blue) for daily online and day 1-3 then 
weekly online protocols are shown for the patient in Figs. 35 and 36. The 
charts show individual DVH lines for each fraction, along with the planned 
dose distribution for the organs at risk. 
 
Uniformly high CTV coverage is visible on the daily online dose-volume 
histogram (Fig. 35). In the weekly online figure, there are several fractions 
where the CTV dose falls off to the left (Fig. 36). The extent of drop of CTV 
coverage is illustrated in Fig. 37.  
 
For the rectal dose, there is a relatively narrow spread of curves for the 
daily online protocol (Fig. 35). With weekly imaging, there is a wider 
spread with rectal dose-volume curves moving to the right of the planned 
dose, indicating higher dose to the rectum in several fractions (Figs. 36). 
Fig. 38 shows that there were four fractions where the rectal V50Gy 
equivalent exceeded 50% in the weekly protocol, compared with none with 
daily imaging. The rectal V65Gy was 21.3% for the weekly protocol 
compared with 17.8% for the daily protocol. There was no clear 
relationship between rectal volume per fraction and rectal dose, with only 
a modest positive correlation (Fig. 39).  
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The bladder volume on the planning scan was 276 cm3. The mean 
treatment bladder volume was 253 cm3 (SD 87 cm3). The wide fluctuation 
in bladder volume that occurs during treatment, despite the use of daily 
cone beam imaging is seen in Fig. 40. The bladder dose distribution 
appears very similar between the two protocols.  This is indicated by the 
bladder V65Gy which is 10.6% in the weekly imaging group and 12.2% in 
the daily imaging group. This is reflective of the portion of bladder close to 
the high-dose volume which is unavoidable even with excellent targeting 
of dose. 
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Fig. 35. Case 1: DVH for CTV, bladder and rectum for daily online 
protocol 
CTV – Red, Bladder – Blue, Rectum – Purple, Planned - Black 
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Fig. 36. Case 1: DVH for CTV and rectum for weekly online protocol 
CTV – Red, Bladder – Blue, Rectum – Purple, Planned - Black
118 
 
Fig. 37. Case 1: CTV V98 for weekly online compared to daily online protocol 
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Fig. 38. Case 1: Rectal V50Gy equivalent for weekly online compared to daily online protocol 
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Fig. 39. Case 1: Rectal V50Gy for daily imaging plotted against rectal volume on individual fractions 
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Fig. 40. Case 1: Bladder V65Gy equivalent for weekly online compared to daily online protocol 
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5.3.2 Case 2 
 
In this case, there was again better CTV coverage dosimetry with daily 
imaging compared to weekly imaging. This is demonstrated in the dose-
volume histograms in Fig. 41 and Fig. 42. There were 6 fractions where 
the CTV V95 was less than 99% with weekly imaging compared with 3 
fractions with daily imaging (Fig. 43). As can be seen in Fig. 44, on each of 
those 6 fractions, a different area of the prostate was outside the target 
dose region. Therefore, the clinical impact in terms of disease control is 
likely to be minimal in this case. 
 
However, the rectal toxicity is likely to be less with daily imaging in this 
case, as the rectal dose parameters are improved. Rectal V50Gy was 
35.9% with daily imaging compared with 41.4% was weekly imaging. 
There were 9 fractions where the rectal V50Gy equivalent was greater 
than 50% in the weekly protocol, compared to none with daily imaging 
(Fig. 45). 
 
The bladder V65Gy was slightly higher in the daily imaging group at 12.7% 
compared to 11.3% with weekly imaging. There was a visible relationship 
between bladder volume and V65Gy (Fig. 46), which was confirmed on 
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correlation analysis (Fig. 47) with a polynomial correlation coefficient of 
0.61. 
 
 
Fig. 41. Case 2: DVH for CTV, bladder and rectum for daily online 
protocol 
CTV – Red, Bladder – Blue, Rectum – Purple, Planned – Black 
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Fig. 42. Case 2: DVH for CTV and rectum for weekly online protocol 
CTV – Red, Bladder – Blue, Rectum – Purple, Planned – Black 
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Fig. 43. Case 2: CTV V98 by fraction for daily CBCT versus weekly protocol
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Fig. 44. Case 2: Lateral projections of 95% isodose for 6 fractions 
where CTV coverage reduced 
Red – areas where CTV not covered by 95% isodose
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Fig 45. Case 2: Rectal V50Gy equivalent by fraction for daily CBCT versus weekly protocol 
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Fig 46. Case 2: Bladder V65Gy equivalent by fraction for daily CBCT versus weekly protocol
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Fig 47. Case 2: Bladder V65Gy equivalent by fraction for daily CBCT 
versus weekly protocol   
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5.5 CBCT margin comparison - Results 
 
I evaluated the effect of CTV-PTV margin reduction if daily imaging was 
used. Margins of 3 and 5 mm were compared to the treatment margin of 7 
mm. The median CTV V95% coverage was 99.98% with daily imaging 
(Table 9). The median coverage was 99.86% and 99.40% with 5 mm and 
3 mm margins respectively.  
 
Table 9. Dosimetric parameters – CTV-PTV margin comparison 
with daily imaging 
Parameter 3 mm 5 mm 7 mm p 
CTV V95 / % (median) 99.40 99.86 99.98 <0.001* 
Rectal V50Gy / % 21.14 26.34 32.48 <0.001† 
Mean rectal dose / Gy 28.99 32.20 36.56 <0.001† 
Rectal D2cc / Gy 70.43 72.39 73.37 <0.001† 
Bladder V65Gy / % 6.18 8.34 10.32 <0.001† 
Mean bladder dose / Gy 18.45 20.75 23.13 <0.001† 
n = 20, CTV – Clinical target volume, PTV – Planned target volume 
*Friedman’s test significant at Bonferroni correction level 0.017 †Repeated 
measures ANOVA with Bonferroni correction 
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However, the number of fractions where 99% coverage was not achieved 
increased progressively with reduced margins. In particular, only 32 
fractions of 37 achieved the coverage target with a 3-mm margin (Fig. 48). 
Rectal and bladder dosimetry showed progressive reduction in dose to 
these organs at risk with smaller margins, although the doses were within 
planning constraints even with the 7-mm margin. 
 
 
Fig. 48. CTV coverage by CTV-PTV margin with daily imaging 
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Chapter 6. Discussion 
 
6.1 Strengths of study 
 
6.1.1 Completeness of dataset 
 
A key strength of this study was the analysis of a complete set of daily 
CBCT images for each patient, allowing full evaluation of the effect of 
frequency of imaging and PTV margin. In particular, any random variation 
in organ position during the whole treatment course could be detected. 
Several previous reported studies have utilized only weekly (Maund et al., 
2014, Pawlowski et al., 2010) or twice-weekly (Hatton et al., 2011) CBCT 
images.  
 
6.1.2 Image quality 
 
The study had the advantage of the use of kV CBCT imaging which has 
better image quality than MVCT images (Varadhan et al., 2009). Previous 
dosimetric studies (Battista et al., 2013, Kupelian et al., 2006) used poorer 
quality MVCT imaging. In my study, there were only a few CBCTs in the 
whole sample where contouring was affected by image quality. As a result, 
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there can be more confidence in delineation of difficult areas such as the 
apex of the prostate and prostate-bladder interface. 
 
6.1.3 Consistency of contouring 
 
All contouring was carried out by the clinical investigator independent of 
the radiographers who carried out CBCT verification. My contours were 
further reviewed independently by an experienced clinical oncologist. The 
use of manual contours was essential for quality assurance. This was 
because commercial automatic contouring programs were not sufficiently 
accurate for use with CBCT, at the time of initiation of this project. 
 
The consistency of contouring was apparent from the minimal variation in 
CTV volume from the planning CT volume (Section 4.3 Fig. 14). The mean 
change in CTV volume from the planning CT was 0.2%. This is much 
better than the 9.2% mean variation reported in another CBCT dosimetric 
study from the United Kingdom (Maund et al., 2014).  
 
6.1.4 Clinical validity 
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The patients in my study had actual treatment shifts that were based on 
CBCT soft-tissue matching. This is in comparison to previous studies 
where CBCT imaging was evaluated but patients had fiducial (Kupelian et 
al., 2006) or portal imaging (Hammoud et al., 2008) verification for 
treatment. Therefore, this study provided the opportunity for the dosimetric 
evaluation of the CBCT verification technique as used in routine clinical 
practice. In the process, we also managed to evaluate the time 
implications of the technique in actual clinical practice. 
 
6.1.5 Assessment of benefit of reimaging 
 
In addition to the treatment verification CBCT, the study also assessed the 
first CBCT in cases where imaging was repeated. This allowed the 
evaluation of the benefit of repeating CBCT imaging in circumstances 
such as rectal distension. There are no previous published prostate 
radiotherapy studies evaluating this practice. 
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6.2 Weaknesses of study 
 
6.2.1 Study patient numbers 
 
The substantial number of cone beam CT scans limited the number of 
patients that could be included in this study. Each patient was imaged 
daily with CBCT during the course of radiotherapy, and had repeat 
imaging if required during a fraction. On average, each patient had 42 
cone beam CT images. Due to the non-availability of commercial auto-
contouring software for cone beam CT, manual contouring had to be done 
for each scan. Due to time constraints, the number of patients had to be 
therefore limited to 20.  
 
However, this would still be the largest series of prostate radiotherapy 
patients with a full set of daily cone beam CT reported in the literature. The 
study numbers also exceeded the number of 16, which was the sample 
size calculated for detection of rectal toxicity reduction (section 5.1.1). 
Investigation of predictive factors for IGRT benefit would require a larger 
sample size. 
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6.2.2 Validation dataset 
 
The validation study was limited to 25 fractions due to processing power 
limitations of the planning software. Ideally, we would have carried out 
validation samples on more patients and included a greater number of 
fractions. However, the density-override method, using a region of interest 
mapping technique, is both time-intensive and resource-intensive. As a 
result, a larger validation study was not possible within the timeframe of 
this research project.  
 
The main premise of our study method was that density-override may not 
be required when a multiple field beam arrangement was used, as in 
modern IMRT. This hypothesis was validated in our sample. The 
technique is also supported by other published literature (Orton and Tomé, 
2004, Schulze et al., 2009, Maund et al., 2014).  
 
However, the method has not been validated with older conformal 
radiotherapy with three fields, where the effect of the variation in 
surrounding tissue density and source-surface distance might be higher. It 
is important to note however that there is no gold standard for dose 
calculation on CBCT at present. 
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6.2.3 Spatial information 
 
Dose-volume histograms provide a concise, quantitative representation of 
dose distributions for radiotherapy plans. Essentially, the three-
dimensional dose distribution on each CT slice is converted into a dose-
volume distribution by assessing the dose received by each voxel.  
 
Therefore, an inherent limitation is the lack of spatial information on the 
distribution of dose (Drzymala et al., 1991). There cannot be any 
assessment of ‘hot spots’ where there is overdosing or ‘cold spots’ due to 
underdosing.  
 
Attempts have been made to overcome this by the use of spatial DVH 
such as the zDVH concept (Cheng and Das, 1999). The zDVH is a 2-D 
analogue of a 3-D DVH. The process involves the generation of DVH data 
referenced to CT slices. This allows evaluation of high-dose regions within 
the volume, even if the overall DVH is satisfactory. However, the zDVH 
concept is not in routine clinical or research use. 
 
The difficulty with assessing three-dimensional distributions for very large 
numbers of CT sets is that it is cumbersome and difficult to quantify. The 
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assessment of spatial dose distribution for all patients was outside the 
scope of this study.  
 
6.2.4 Tumour position 
 
My study did not evaluate the actual tumour position within the prostate, 
due to obvious limitations of CT imaging for that purpose. Patients within 
this study group also did not have MRI imaging fused to the planning CT. 
Therefore, I could not accurately determine if the same area of tumour 
was missed in these fractions. I did however evaluate the area of CTV 
missed in each fraction in the case studies during the study (section 5.3). 
The results of our study indicate the even greater need for regular 
imaging, if boosting of the primary tumour is being considered. 
 
6.2.5 Seminal vesicle coverage 
 
There is evidence that there is differential motion of seminal vesicles, with 
a larger magnitude of motion compared to the prostate (Liang et al., 2009). 
However, the risk of seminal vesicle invasion differs depending on the 
prostate cancer risk stratification. It is approximately 16% in in patients 
with PSA in the range of 10-20 ng/ml (Zlotta et al., 2004). In the clear 
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majority of cases only the base of the seminal vesicles is involved. In a 
detailed pathologic analysis of 344 patients, only 7% had involvement of 
more than 1 cm of the seminal vesicle, and only 1% had involvement more 
than 2 cm (Kestin et al., 2002). 
 
In this study, the seminal vesicles were not contoured separately. This 
was because only the base of the seminal vesicles was treated, as study 
patients were in intermediate risk group. During treatment planning, in 
most patients they were contoured by the treating oncologist as part of a 
common CTV. To enable comparison with the planned treatment, the 
same protocol was followed for all patients and a combined CTV was 
created. Therefore, it is not possible to determine from this study whether 
seminal vesicle coverage is differentially affected by the IGRT schedule or 
margin. 
 
6.2.6 Biological dose evaluation 
 
This study has not evaluated radiobiological parameters such as tumour 
control probability (TCP) and normal tissue complication probability 
(NTCP). These are obtained using models which use a number of 
assumptions. This includes the tumour alpha-beta value, for which there 
are varying estimates in prostate cancer.  
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Research tools are available to derive TCP and NTCP values from a DVH 
curve (Sanchez-Nieto and Nahum, 2000, Warkentin et al., 2004, Tsougos 
et al., 2009). TCP and NTCP estimates are very sensitive to relatively 
small changes in shape of DVH curves (Drzymala et al., 1991) 
 
There is a potential weakness to creating cumulative dose-volume 
histograms using simple averages, due to potential differences in 
differences in volume in each dose bin (Sanchez-Nieto and Nahum, 2000). 
The treatment planning system used in our centres did not allow a 
cumulative dose deposition estimate on a voxel-by-voxel basis for the 
whole course of radiotherapy. As a result, individual dose-volume 
histograms were obtained for each fraction. A crude summation of dose-
volume histograms would have resulted in an inaccurate estimate of TCP 
and NTCP, and was therefore not attempted. 
 
6.2.7 Bladder volume variation 
 
Due to the limited scan length of the CBCT, there were six patients where 
the whole of the bladder was not included in the CBCT imaging. In these 
patients, the dome of the bladder was not available for contouring, leading 
to a lower contoured bladder volume. This may limit the comparability of 
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the bladder dosimetric parameters to the planned dose distribution. 
However, it would not affect the comparison of imaging protocol and PTV 
margin evaluation.  
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6.3 Target volume coverage 
 
My work shows that there are statistically significant improvements in 
target volume coverage during radical prostate radiotherapy when daily 
CBCT imaging is used. The absolute magnitude of benefit of daily imaging 
is small over the course of radiotherapy. This is because the effect of the 
fractions where geographic miss occurs is averaged out over the whole 
course. 
 
The magnitude of benefit is greater when considering the proportion of 
fractions where target objectives are met. This is of particular importance if 
hypofractionated treatment regimens are used. A study using Monte Carlo 
simulation methods reported a small but consistent reduction in tumour 
control probability (TCP) of approximately 1% due to geometric uncertainty 
in hypofractionated regimens (Craig et al., 2003). The national IGRT 
survey conducted during this project showed that 16% of centres use a 60 
Gy in 20 fractions regimen. The effects of geographic miss in a 20-fraction 
regimen will be proportionately higher than in the 37-fraction regimen used 
in our study.  
 
The highest benefit was seen on treatment days where intra-fractional re-
imaging was performed due to rectal distension on the initial scan. On 
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these fractions, there was a mean increase in CTV V98 of 5.1%. This 
should be counterbalanced against the additional radiation dose that is 
introduced through re-imaging. 
 
There are difficulties in comparing the results of this study to other 
published data. A major limitation of similar studies (Maund et al., 2014, 
Pawlowski et al., 2010, Hatton et al., 2011) is that a full data set was not 
available or analysed in those studies. Therefore, actual daily data was not 
available for accurate protocol comparisons. One other study using 
simulated protocol comparisons with more complete data (Battista et al., 
2013) used different dose metrics of D95 and TCP to report results.  
  
145 
 
6.4 Organ at risk dose 
 
DVH parameters have been demonstrated to be useful in assessing the 
risk of acute and chronic organ toxicity (Huang et al., 2002b, Vargas et al., 
2005).  
 
Huang et al. investigated 163 patients treated with 3-D conformal prostate 
radiotherapy to a dose of 74-78 Gy. They assessed chronic rectal toxicity 
at 6 years in relation to dosimetric, anatomic and clinical factors. The 
dosimetric factors were clearly associated with rectal toxicity. In particular, 
the percentage of rectal volume treated correlated significantly with 
toxicity, at all dose levels. Clinical factors had limited predictive value. 
 
Vargas et al evaluated 331 patients who had image-guided radiotherapy 
for localized prostate cancer, in a phase 2 dose escalation trial. Toxicity 
was evaluated using the NCI CTC version 2.0. They found that rectal wall 
V50 – V70 was closely predictive of chronic rectal toxicity >= grade 2. 
Absolute rectal volumes were far less predictive than relative rectal 
volumes. The dose level used did not predict chronic toxicity. Acute rectal 
toxicity during treatment also predicted chronic toxicity. 
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I selected V50Gy as a DVH parameter to evaluate, based on the above 
studies and the widespread use of this parameter in the UK during 
radiotherapy planning. My study has confirmed that V50Gy is significantly 
reduced with the use of daily imaging in comparison to less frequent 
imaging schedules. This would counterbalance the increased pelvic 
radiation exposure due to higher overall imaging dose during radiotherapy.  
 
The D2cc high dose value was not reduced by daily IGRT. This is likely to 
be due to the close approximation of the high-dose region of rectum to the 
prostate target volume. Improved accuracy of prostate irradiation would 
result in this region of the rectum continuing to receive a high dose with 
image guidance. 
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6.5 Investigation of factors predictive of benefit from IGRT 
 
Rectal distension on planning CT scan has been considered a predictive 
factor for biochemical failure during prostate radiotherapy (de Crevoisier et 
al., 2005, Heemsbergen et al., 2007, Engels et al., 2009). However, these 
studies were done on patients treated without volumetric image guidance. 
Patients in the de Crevoisier series had verification using skin marks and 
weekly portal imaging. The Heemsbergen study patients had offline 
verification using portal imaging. In the Engels series, portal imaging was 
used again with a minority of patients having fiducial markers.  
 
There have also been dosimetric studies which appear to show a 
relationship between planning CT rectal volume and reduced CTV 
coverage. A daily CBCT study showed that rectal volume at planning > 
100 cm3 was associated with lower CTV coverage (Sripadam et al., 2009). 
However, in this study, the actual verification modality used during 
treatment was offline portal imaging.  
 
Another study has shown that higher bladder volume, rectal cross-
sectional area and body mass index may be predictive of benefit from 
fiducial-based IGRT (Munck af Rosenschold et al., 2014).  They analysed 
the shift results of 267 patients and estimated interfraction uncertainty to 
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arrive at this conclusion. However, there was no attempt to review actual 
dose distributions achieved during treatment. 
 
In my study where patients were treated daily online cone beam CT 
verification, the rectal volume on the planning CT scan was not predictive 
of CTV coverage. This is in line with more recent published clinical data 
which show that outcomes are not affected by the planning CT scan rectal 
volume if an adaptive IGRT strategy with cone beam CT is used (Park et 
al., 2012).  
 
In my study, the clear majority of patients benefited from daily CBCT 
imaging with no pre-treatment predictive factors identified. However, a 
larger cohort of patients may be required to investigate factors which 
predict for the actual magnitude of benefit from CBCT image-guidance. 
 
The relationship between bladder and rectal volume during treatment with 
organ-at-risk dose is in line with results reported from a smaller study 
(Chen et al., 2016). Their study used a cone beam calibration curve 
method and obtained comparable results of correlation shown only with 
mean bladder dose on multivariable analysis. This relationship does 
highlight the importance of maintaining a full bladder during treatment. 
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6.6 Concomitant dose 
 
The use of daily verification imaging requires consideration of concomitant 
dose to organs at risk. Potential long-term effects of radiation include 
deterministic and stochastic effects. Deterministic effects are dose-related, 
and of relatively little importance in the context of radiotherapy-related low-
dose CBCT use. Stochastic effects occur due to chance, and do not have 
a specific dose threshold. Stochastic effects include the small risk of 
carcinogenic effects and even rarer heritable effects. 
 
There is a small additional second cancer risk with additional imaging. 
This should be borne in mind when patients are informed of risks of 
treatment. This risk can be estimated using various models. One study 
has estimated a lifetime attributable risk (LAR) of up to 400 second 
cancers per 10000 persons with a course of 30 CBCTs (Kim et al., 2013), 
using the BEIR model. Their estimate is unusually high compared with 
another published study which estimated risk for CBCT use in breast 
radiotherapy (Donovan et al., 2012). Moreover, the US National Research 
Council which developed the BEIR model for risk calculation has admitted 
that there are many broad assumptions which could limit the accuracy of 
such LAR estimates (Council, 2006). 
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Previous simulation studies have shown that CT imaging during 
radiotherapy has only a small fractional contribution to the total radiation 
dose received by critical organs (Harrison et al., 2006, Chow et al., 2008, 
Harrison, 2004). This has also been confirmed by the International 
Commission for Radiological Protection (ICRP) in their latest guidelines on 
CBCT use (Rehani et al., 2015).  
 
Chow et al. used Monte Carlo simulation to calculate the additional dose 
delivered to various pelvic organs from CBCT during prostate 
radiotherapy. They found that there was minimal effect on the rectum and 
bladder dose-volume histograms from the CBCT. The highest additional 
dose was to the femoral heads, but despite this the femoral heads were 
well below tolerance limits. Their study estimated an increase in rectal 
NTCP of 0.5% due to the use of CBCT verification during radiotherapy, but 
this was counterbalanced by an estimated 3% reduction in rectal NTCP if 
margins could be reduced from 10 mm to 5 mm. 
 
Harrison et al. used an anthropomorphic phantom to calculate concomitant 
doses. On their highest exposure protocol of 26 CTs, the proportion of 
dose due to CT was 3% to colon (including rectum) and 1% to bladder. 
Deng et al. used Monte Carlo simulation and estimated that 3.2% of colon 
and bladder dose could be attributed to CBCT dose (Deng et al., 2012). 
Their study found that there was lower concomitant dose to most organs if 
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a full-fan mode was used for CBCT acquisition. As would be expected, a 
shorter scan length also reduced dose exposure. 
 
Modern second-generation kV CBCT imagers deliver lower exposure dose 
than MV portal imaging, although higher dose than kV portal imaging 
(Ding and Munro, 2013). Reduction in exposure doses have even been 
achieved by manufacturers improving their imaging settings between 
version upgrades (Ding et al., 2010). 
 
In our study centres, the average measured concomitant dose to the 
pelvis was 30 mGy per on-board CBCT exposure. This is in line with 
concomitant dose reported by other centres for this treatment site (Stock 
et al., 2012, Amer et al., 2007). The nominal total concomitant dose would 
be approximately 0.9 Gy per treatment course with daily imaging. The 
reduction in rectal dose due to increased accuracy with daily CBCT in our 
study would further reduce concomitant dose. 
 
There are clear limitations to adding concomitant dose from kV imaging 
directly to MV radiotherapy dose. This is because of intrinsic differences in 
the type of energy. kV energy has greater photoelectric effects and lead to 
increased skin and bone dose (Harrison et al., 2006, Downes et al., 2009). 
The differences in dose distribution would therefore render simple 
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summation of doses from the two modalities inappropriate. Calculation of 
stochastic risk using BEIR type models for this dataset was outside the 
scope of this work. 
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6.7 Cost-effectiveness of CBCT verification 
 
If daily imaging is used for all patients, the incremental time implications 
are modest. An economic analysis study in France was conducted in 
patients undergoing prostate radiotherapy (Perrier et al., 2013). It showed 
an increase in treatment time by 7.3 minutes per fraction with the use of 
daily CBCT in comparison to weekly. A further European study has shown 
that the additional time required for prostate cases using Elekta CBCT 
equipment was 5.5 minutes (Korreman et al., 2010).   
 
In our study, the mean time for CBCT acquisition and radiographer review 
was 3.8 minutes (range 2.2 to 7.7 minutes). However, this was across 
three UK centres where daily CBCT review was well-established as 
routine practice for prostate radiotherapy staff. A continuing program of 
radiographer induction and training is vital for radiotherapy centres which 
incorporate this IGRT strategy. Once training has been established, the 
interobserver variation in CBCT interpretation can be minimized.  
 
A study comparing CBCT shifts between trained radiographers and 
oncologists has shown that there is minimal interobserver variation 
(Jereczek-Fossa et al., 2014). They found substantial agreement (kappa > 
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0.6) in 10 out of 16 comparisons and moderate agreement in the 
remainder. 
 
The additional cost implications of CBCT installation and quality assurance 
also should be considered. This may vary widely between countries. A 
Canadian study (Ploquin and Dunscombe, 2009) showed a relatively large 
incremental cost of 2592 euros for a 35-fraction treatment with daily 
CBCT. This is in comparison to 1772 euros with daily portal imaging. They 
used a dosimetric parameter ΔEUD to quantify the improvement with 
IGRT techniques. The incremental cost per ΔEUD of 3379 euros for daily 
CBCT in comparison to 2310 euros daily portal imaging was reported. 
However, they have made a key assumption in their calculation that both 
portal imaging and CBCT are equivalent in imaging characteristics. There 
is evidence that this assumption is incorrect, as discussed earlier in this 
thesis. 
 
The European study (Perrier et al., 2013) showed that the incremental 
cost of daily CBCT per patient was lower at 679 euros. The cost of 
fiducial-based IGRT was even lower at 187 euros. However, a substantial 
proportion of this difference was due to the difference in cost of the linear 
accelerator with on-board imaging. Most UK radiotherapy centres already 
have appropriately equipped linear accelerators according to our IGRT 
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survey results. Therefore, the incremental cost of daily CBCT in the UK is 
likely to be lower than in this European study.  
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6.8 PTV margin analysis 
 
The PTV margin analysis indicates that a reduction of margin to 5 mm is 
feasible with daily CBCT imaging. This is comparable to previous studies 
which have used fiducial-based IGRT (Pawlowski et al., 2010).  Their 
study which utilized prostate fiducials and weekly CBCT imaging 
demonstrated that reduction of margin to 4 mm (with 3 mm posteriorly) is 
feasible. 
 
I used the systematic and random errors generated from analysis of shifts 
to compare our dosimetric margin results with that obtained from a margin 
formula. The Stroom formula (Stroom et al., 1999) was used, as this is one 
of the earliest validated  margin formulae. It also uses a CTV V95 
coverage threshold target of 99%, which is in line with the dosimetric 
coverage target for each fraction in my study. The other major formula is 
the van Herk formula (van Herk et al., 2000) which uses a population 
based coverage threshold of 90% of patients covered by the minimum 
95% dose to CTV. 
 
If the Stroom formula was used on our dataset to provide an estimate of 
required margin, it would be 6.9 mm (left-right), 4.2 mm (sup-inf) and 9.8 
mm (ant-post). The magnitude of setup error in the left-right direction was 
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unexpected but is in line with a previously reported series (Mayyas et al., 
2013). In practice, the actual random and systematic errors could be 
minimized by daily online matching. These results therefore illustrate the 
conservative nature of margin formulae, and the importance of assessing 
actual dosimetry during treatment. 
 
Residual errors which could not be assessed in our study have also to be 
taken in to account when considering the overall margin used between 
CTV and PTV. These include intrafraction motion (Kron et al., 2010, 
Thomas et al., 2013, Huang et al., 2002a) during prostate radiotherapy.   
 
Huang et al. evaluated intrafraction shifts during prostate radiotherapy 
using a B-mode ultrasound system. They demonstrated shifts of 0.01 mm 
(+/- 0.4 mm), 0.2 mm (+/- 1.3 mm) and 0.1 mm (+/- 1.0 mm) in the left, 
anterior and superior directions. The intrafraction motion was clearly less 
than interfraction motion in their study. 
 
Kron et al. assessed intrafraction motion by using orthogonal x-rays done 
pre- and post-treatment in a series of 184 patients. They found a mean 
three-dimensional vector shift of 1.7 mm (range 0 – 25 mm), with no trend 
towards any particular direction.  There was no improvement in the 
intrafraction error through the course of radiotherapy.  
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Thomas et al. assessed intrafraction motion using MVCT images in helical 
tomotherapy for prostate cancer. They calculated an additional required 
margin of 2.2 mm, 2.1 mm and 2.1 mm in the left-right, superior-inferior 
and antero-posterior directions to account for intrafraction error.  
 
Patients in our study were treated with step-and-shoot IMRT where 
treatment time would be influenced by the number of fields used. 
However, intrafraction motion will be of lesser importance with modern 
IMRT techniques such as arc treatment, where treatment times are 
shorter. This was confirmed in a study evaluating intrafraction motion 
during arc radiotherapy (Baker and Behrens, 2016). The investigators 
found that 3-D vector displacement more than 2 mm occurred in 12% of 
fractions and only 4% showed displacements larger than 3 mm during a 
typical 2.5-minute fraction. It also exemplifies the need for individual 
centres to calculate setup margins based on the particular combination of 
imaging protocol and equipment used for radiotherapy treatment of 
prostate patients. 
 
The other type of residual error is registration error during soft-tissue 
matching. Morrow et al. assessed this error in relation to different 
modalities of verification CT imaging (Morrow et al., 2012). They found 
that kV CBCT had lower registration errors than MVCT due to better 
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image quality. The inter-observer variability ranged from 0.6 to 2.5 mm for 
the kV imaging in comparison to 1.7 to 3.2 mm for MV CT imaging. The 
intra-observer variability was much less at approximately 1 mm. The total 
additional PTV margin required to correct for these residual errors has 
been estimated to be up to 3 mm in a study where CBCT imaging was 
repeated post-treatment (Letourneau et al., 2005). 
 
The results of my investigation also caution against further margin 
reduction to 3 mm. This is because there would then be increasing 
numbers of radiotherapy fractions where CTV coverage is reduced. A 5-
mm margin all around the CTV provides a good balance of target 
coverage and toxicity reduction. Individual centres should evaluate their 
PTV margins in relation to the imaging protocol, to optimally use CBCT 
verification during prostate radiotherapy. 
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Chapter 7. Conclusion 
 
This MD(Res) project has provided valuable information for optimization of 
verification imaging during prostate radiotherapy. During preliminary work, 
I developed and validated a dose calculation strategy on cone beam CT. A 
national survey of prostate IGRT practice confirmed that the principal 
difference in verification strategy was the use of daily vs weekly imaging.  
 
Initial work showed the drops in coverage that occur if a bone match 
strategy is used compared with soft tissue matching. Further analysis of 
actual dose coverage during each fraction of radiotherapy has allowed an 
accurate estimation of the quantitative benefit of daily imaging.  
 
The study showed that 90% of patients had improved target coverage with 
daily online in comparison to weekly online imaging. A median of 37 
fractions achieved CTV coverage with daily imaging compared with 34 
fractions with a weekly online protocol. 80% of patients had a reduction in 
rectal dose with the daily protocol. Margin reduction to 5 mm with 
adequate target coverage was feasible with daily imaging. 
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In conclusion, daily online CBCT verification improves CTV coverage and 
reduces rectal dose during IGRT for prostate cancer. Daily CBCT imaging 
allows reduction of CTV-PTV margin for radiotherapy. 
 
As a result of this MD (Res) project, there have been advances in 
knowledge in the following areas: 
1. Understanding the current state of image-guided radiotherapy 
practice for prostate cancer in the United Kingdom 
2. Validation of a method for dose calculation on cone beam CT for 
verification and research purposes 
3. Quantification of the dosimetric benefits of daily CBCT verification 
during prostate radiotherapy 
4. Providing a dosimetric approach for deciding on the CTV-PTV 
margin in prostate radiotherapy 
 
The utilization of MRI imaging will revolutionize radiotherapy verification in 
prostate cancer in the future. Further research will be required to develop 
MRI-guided prostate radiotherapy. The dose calculation techniques and 
results of this study will be useful in design of verification strategies on 
different platforms.  
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Appendix 1 – National IGRT Survey Tool 
 
1. Name of radiotherapy centre 
 
2. Please enter your job designation 
 
3. How many new patients with prostate cancer were treated with 
radical radiotherapy in February 2014 in your centre? 
 
4. What type of planning is used for radical prostate radiotherapy 
patients? Please select all applicable 
a. 3-4 field conformal      
b. Intensity-modulated (static beam) 
c. Volumetric modulated arc therapy (eg. RapidArc) 
d. Tomotherapy 
e. Cyberknife 
f. Linac-based stereotactic RT 
g. Other…. 
 
5. If intensity-modulated planning is used for radical prostate 
radiotherapy, what percentage of patients is planned in this way? 
i. % 
 
6. What dose-fractionation regimens are used for radical prostate 
radiotherapy in your centre? Please select all applicable 
a. 78 Gy/39# 
b. 74 Gy/37# 
c. 50 Gy/16# 
d. 60 Gy/20# 
e. 57 Gy/19# 
f. Other – please specify 
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7. Are fiducial markers used for radical prostate radiotherapy in your 
centre? 
a. For all patients 
b. Some patients 
c. Not at all 
d. If fiducial markers are used for some patients, please specify 
indication/s 
 
8. Who inserts the fiducial markers for prostate radiotherapy? 
a. Consultant Oncologist 
b. Consultant Urologist 
c. Consultant Radiologist 
d. Other – please specify 
 
9. How many fiducial markers are inserted in each prostate 
radiotherapy patient in your centre? 
 
10. Are prostate rectum spacers used in your centre for radiotherapy? 
a. Yes 
b. No 
 
11. What bowel preparation protocol is used in your centre for prostate 
radiotherapy? 
a. No specific preparation 
b. High-fibre diet information 
c. Daily micro-enema 
d. Other – please specify 
 
12. Please outline your bladder filling protocol for prostate radiotherapy. 
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13. What is the main verification imaging technique that is used for 
radical prostate radiotherapy in your centre? 
a. Orthogonal portal MV imaging 
b. Orthogonal portal KV imaging 
c. 3-D cone beam CT imaging with soft tissue matching 
d. Fiducial markers + KV imaging 
e. Fiducial markers + cone beam CT 
f. Fiducial markers + KV imaging + cone beam CT 
g. Other – please specify 
 
14. What is the frequency of verification imaging for prostate IGRT in 
your centre? 
a. Day 1-3, followed by weekly 
b. Day 1-5, followed by weekly 
c. Daily 
d. Other – please specify if you have different protocols for 
different imaging 
 
15. If cone beam CT is used, what is the frequency of use during 
prostate radiotherapy? 
a. Daily 
b. Weekly 
c. Other, please specify 
 
16. Please specify if cone beam CTs are repeated during a fraction if 
needed 
 
17. What method of correction do you use for prostate IGRT? 
a. Offline 
b. Online (zero tolerance action level protocol) 
c. Online (No Action level protocol) 
d. Other – please specify 
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18. If online correction with a No Action level protocol is used, please 
specify your action level in mm  
 
19. If systematic correction is used, what threshold (mm) do you use for 
systematic correction? 
 
20. If applicable, what threshold in mm do you use for gross errors to 
recheck immobilization and setup? 
 
21. Comments (optional) 
 
Thank you for your participation in this survey 
 
  
190 
 
Appendix 2 – List of publications arising from this 
research study 
 
1. Ariyaratne H, Chesham H, Alonzi R. Image-guided radiotherapy for 
prostate cancer in the United Kingdom: a national survey. British 
Journal of Radiology 2017; 90(1070). 
 
2. Ariyaratne H, Chesham H, Pettingell J, Alonzi R. Image-guided 
radiotherapy for prostate cancer with cone beam CT – dosimetric 
effects of imaging frequency and PTV margin. Radiotherapy and 
Oncology 2016; 121(1): 103-108. 
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Appendix 3 – List of conference presentations 
arising from this research study 
 
1. Ariyaratne H, Alonzi R. Rectal and bladder dose-volume 
relationships during image-guided radiotherapy for prostate cancer. 
Oral and poster presentation at NCRI Conference, Liverpool, Nov 
2017 
 
2. Ariyaratne H, Alonzi R. Image-guided radiotherapy for prostate 
cancer – quantification of benefit of daily online CBCT imaging. 
Poster presentation at NCRI Conference, Liverpool, Nov 2017 
 
3. Ariyaratne H, Chesham H, Alonzi R. Image-guided radiotherapy 
strategies for prostate cancer in the United Kingdom. Poster 
presentation at UKRO 2016, Jun 2016 
 
4. Ariyaratne H, Chesham H, Alonzi R. Target coverage during image-
guided radiotherapy for prostate cancer - how relevant is the initial 
rectal volume? Poster presentation at NCRI Conference, Liverpool, 
Nov 2015. Awarded National Cancer Research Institute Prize 
 
5. Ariyaratne H, Chesham H, Pettingell J, Sikora K, Alonzi R. 
Comparison of cone beam CT imaging protocols in image-guided 
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radiotherapy for prostate cancer. Poster presentation at 3rd ESTRO 
Forum, Barcelona, Apr 2015 
 
6. Ariyaratne H, Chesham H, Pettingell J, Alonzi R. Image-guided 
radiotherapy in prostate cancer: validation of a dose calculation 
method based on cone beam CT contours. Oral presentation and 
National Cancer Research Institute Prize Award at NCRI 
Conference, Liverpool, Nov 2014. Shortlisted for RCR Ross Prize. 
 
7. Chesham H, Ariyaratne H, Pettingell J, Alonzi R, Walsh K. Reduced 
PTV margins for prostate IMRT with daily on-line IGRT: a 
retrospective analysis. Poster presentation at ESTRO 33, Vienna, 
Apr 2014. Awarded Best Poster Award. 
 
8. Ariyaratne H, Chesham H, Pettingell J, Sikora K, Alonzi R. 
Dosimetric effects of image-guided radiotherapy using daily online 
cone beam CT for prostate radiotherapy. Poster presentation at 
ESTRO 33, Vienna, Apr 2014 
 
 
